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The following dissertation discusses the role of Aβ42 dependent hyperactivation of AMPK 
mediating synaptic loss through coordinated Mff-dependent mitochondrial fission and Ulk2-
dpendent mitophagy in dendrites of PNs. In Chapter 1, I provide a brief background on 
Alzheimer’s disease and the cellular and molecular mechanisms that have been relevant to the 
pathogenesis of the disease including disruption on mitochondrial homeostasis and autophagy. In 
Chapter 2, I discuss the findings of my main project describing the role of Aβ42 induced 
mitochondrial remodeling leading to synapse loss in vitro and in vivo in part by hyperactivation 
of CAMKKII-AMPK. Chapter 3 covers a review article that I participated in in examining the 
role of mitochondria in various ND. In Chapter 4, I discuss about a project I was involved in in 
examining the mechanism behind maintaining mitochondrial morphology in axon versus 
dendrite and its functional consequence. In Chapter 5, I end the dissertation by highlighting key 
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Chapter 1: General Introduction 
1.1 Alzheimer’s disease  
1.1.1 Clinical and pathological features of Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is the most prevalent form of dementia leading to socially 
devastating cognitive defects with no effective treatment. Symptoms of AD include memory and 
language impairment as well as executive dysfunction that disrupts daily life activities. Patients 
show impairment particularly on episodic memory tests that require a combination of cognitive 
procedures, including recognition, recalling, and associated learning (Weintraub, Wicklund, & 
Salmon, 2012). Other atypical symptoms include visual and pattern recognition problems as well 
as personality changes (Scheltens et al., 2016). In the year of 2017, around 5.5 million 
Americans of all ages are estimated to have suffered from AD, of which around 5.3 million are 
over the age of 65. AD and AD-like dementia is also one of the costliest conditions in society, as 
the total cost of health care and long-term care for these diseases in 2017 alone is estimated at 
$259 billion (2017 Alzheimer’s Disease Facts and Figures).  Therefore, AD is becoming one of 
the most critical global public health issues. 
 
AD was first described in 1906 by Alois Alzheimer and Oskar Fischer at around the same 
time. On a macroscopic level, AD patients display gross atrophy of the brain. A closer 
examination of post-mortem samples identified a build up of amyloid plaques that surround 
dystrophic neurites, intracellular neurofibrillary tangles (NFT), and neuronal loss (Figure 1). The 
two hallmark lesions now characterize AD: amyloid plaques composed of aggregated amyloid-
beta (Aβ) peptides and NFT composed of aggregated,  
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hyperphosphorylated tau. Interestingly, neuronal death is more prominent in specific areas of the 
brain such as the layer II of the entorhinal cortex, CA1 of the hippocampus, and certain parts of 
the temporal, parietal, and frontal cortex. Because these regions are involved in learning, 
episodic memory, and higher intellectual processing, cell deaths in these regions likely explain 
the gradual degeneration of cognitive function in patients (Holtzman et al., 2011; Weintraub et 
al., 2012).   
 
The first set of criteria for AD diagnosis established in 1984 was primarily based on 
Figure 1. Neuropathological hallmarks of Alzheimer’s disease. Brain sections from 
Alzheimer’s disease and Lewy body disease patients; (A) H&E staining in sections from 
frontal cortex displaying extracellular plaques; (B) H&E staining in sections from 
hippocampus showing intracellular tangles; (C) Silver staining showing both extracellular 
plaques and intracellular tangles, two pathological hallmarks of AD; (D) 
Immunohistochemistry staining for Aβ antibody to highlight plaques; (E) 
Immunohistochemistry staining for tau antibody to highlight tangles; (F) H&E staining 
from frontal cortex displaying Lewy body in layer V neurons  (Serrano-Pozo, Frosch, 
Masliah, & Hyman, 2011)	
 4	
clinical symptoms. However, the advent of various imaging and biomarker development 
suggests that the histo-pathological hallmarks can precede clinical symptoms by at least 10- 15 
years (Scheltens et al., 2016). Thus, current research focuses on developing diagnostic tools, 
including cerebral spinal fluid (CSF) biomarkers and imaging techniques, to identify patients 
before any clinical symptoms. CSF biomarker tools detect levels of Aβ, tau, and phosphorylated 
tau, which all contribute to the amyloid plaques and NFT. Diagnostic imaging techniques include 
hippocampal volumetry to monitor changes of tissue size as well as various Positron Emission 
Tomography (PET) techniques. The two primary PET scan imaging tools include using ligands 
for Aβ and tau, such as florbetapir, florbetaben, and flutemetamol as well as 18F-
fluorodeoxyglucose (FDG) to measure glucose uptake by neurons and glial cells, as 
hypometabolism patterns are observed in various AD patients (Scheltens et al., 2016). 
 
On the treatment end of the disease, there are currently four available drugs for dementia 
patients. Three of the four, donepezil, rivastigmine, and galantamine, are cholinesterase 
inhibitors, preventing the breakdown of acetylcholine neurotransmitter, which is hypothesized to 
mildly improve symptoms in some patients (Scheltens et al., 2016). The last available drug is 
memantine, a glutamate antagonist. Although the current drugs can alleviate some of the 
symptoms in some patients, they are not a curative treatment nor do they slow down the 
progression of the disease (2017 Alzheimer’s Disease Facts and Figures). Several antibody-based 
treatments targeted to either various regions of Aβ or the enzymes involved in amyloid precursor 
protein (APP) processing (introduced further later) have made it to clinical trials with little to no 
success to this date. Immunotherapy designed to target Aβ include bapineuzumab, which target 
the N-terminus of Aβ, solanezumab, which binds to the soluble form of Aβ, and gantenerumab, 
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which bind to Aβ peptide. Many of these immunotherapies resulted in unsuccessful trials 
suggesting the need for basic research to better understand the progression of the disease as well 
as to identify key therapeutic targets. However, one of the main limitations of these clinical trials 
was that they were performed on symptomatic patients at stages during the disease progression 
when it might be difficult to reverse some of the synaptic and neuronal loss. With the 
advancement in biomarkers used to identify patient populations at earlier stages of the disease, 
i.e. in pre-symptomatic patients characterized by mild cognitive impairments, new clinical trials 
targeting Aβ and/or Tau might lead to better outcomes (Cappa, 2018). 
 
 1.1.2 Genetics of AD and APP processing 
The two types of AD include the early-onset AD (EOAD), which generally occurs before 
the age of 65 and is considered to be the more aggressive form of the disease, or late-onset AD 
(LOAD), which is the more common, sporadic form of the disease associated with aging. 
Currently, all the dominant mutations identified to cause EOAD are either on the type-I trans-
membrane protein called APP or on the catalytic sites of proteases, Presenilin 1 and 2 (PS1 and 
PS2), which are involved in the cleavage of APP (Selkoe & Hardy, 2016). APP is located on 
chromosome 21 and is ubiquitously expressed. It undergoes various cleavage processes by 
different enzymes. In the non-amyloidogenic pathway, APP is cleaved by α secretase (Figure 2). 
This is followed by γ secretase cleavage that ultimately produces various lengths of Aβ peptide, 
including the non-toxic 40 amino acid long Aβ peptides (Nunan & Small, 2000). In the 
amyloidogenic pathway, APP is cleaved first by β secretase, which is primarily composed of 
unique membrane beta-secretase 1 (BACE1), a member of the pepsin family of aspartyl proteins. 
This is followed by γ secretase that produces longer species of Aβ, including the 42 amino acids 
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long Aβ peptide (Aβ42) (Figure 2). Aβ42 peptides are hydrophobic and therefore have greater 
tendency to aggregate, forming various oligomeric species and ultimately amyloid plaques. It is 
thought that the aggregated forms of Aβ42 causes various toxic events including the 
synaptotoxic effects on excitatory pyramidal neurons (further discussed in the next section).  
It is important to note that there is a range of soluble Aβ species, including dimers, 
trimers, oligomers, midrange oligomers, and Aβ plaques. Although Aβ dimers have been 
detected, trimers are the more abundant species and therefore thought to be preferentially 
formed. AD mouse model Tg2576 that overexpress APPSWE mutations associated with EOAD 
(discussed further in the next section), secrete trimers as early as embryonic stage 14 and 
throughout its life span, rising steadily with age. Based on this higher level of Aβ trimers 
(13kDa), Aβ trimer oligomerization is thought to produce oligomeric species based on multiples 
of three, such as hexamer (27kDa), nonamers (40kDa), dodecamers (56kDa), and so on. 
Interestingly, in Tg2576 mice, cognitive decline begins around 6 months of age when 
dodecamers, Aβ*56, starts to appear and stabilize (Lesne et al., 2006). Build up of Aβ*56 has 
also been observed in other AD mouse model including the J20, which is introduced described in 
the next section (Larson & Lesne, 2012).  
More than 30 mutations on APP have been identified to cause EOAD (Karch, Cruchaga, 
& Goate, 2014). Some of the mutations in the APP known to cause EOAD include the APP 
Swedish (APPSWE) mutation KM670/671NL and APP Indiana (APPIND) mutation V717F near 
the β and γ secretase cleavage sites, respectively (Figure 2). The most common mutations that 
cause EOAD are found on the PS1 and PS2 proteins, which are active components of the γ 
secretase complex including PS1 M146I (Gotz & Ittner, 2008). Ultimately, these mutations drive 
the production of the toxic Aβ42 peptides, increasing the ratio of Aβ42/Aβ40 (Holtzman et al., 
 7	
2011; Karch et al., 2014; Lerdkrai et al., 2018). It is interesting to note that no mutation on tau 
has been associated with EOAD. However, mutation on tau has been associated with 
frontotemporal dementia, another form of dementia linked with more behavioral changes and 
characterized by just NFT of hyperphosphorylated tau. 42 known mutations on tau gene 
including N279K, ΔK280, P301L, and P301S have been associated with frontotemporal 
dementia. Because these mutations can lead to NFT and neuronal cell loss, mutations on tau have 
also been used to model AD, often in combination with APP mutations (Gotz & Ittner, 2008). 
 
Another genetic evidence that the Aβ42 accumulation leads to neurotoxic events include 
Figure 2. APP processing and genetic mutations associated with EOAD. Model of how 
APP is cleaved by various enzymes and the mutations commonly found in EOAD. APP is a 
trans-membrane protein that can undergo cleavage processing by α secretase followed by γ 
secretase that produces various lengths of Aβ peptides, including the non-toxic 40 amino 
acid long Aβ peptides. However, processing by β secretase followed by γ secretase produces 
42 amino acids long Aβ peptide (Aβ42), which form oligomers that are toxic to neurons. All 
the mutations associated with EOAD are found on the APP, including the ones highlight in 
the figure APPSWE mutations KM670/671NL and APPIND mutation V717F, or on PS1 and 
PS2, which are active enzymatic components of the γ secretase. These mutations increase 
the production of Aβ42 species (Holtzman, Morris, & Goate, 2011).  	
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a rare point mutation on APP (A673T), which results in lifelong reduction of APP cleavage 
processing by β secretase. This mutation not only prevents amyloid plaque formation at older 
age, but also lowers risk of AD and other age-related dementia (Jonsson et al., 2012). Therefore, 
much of the genetic evidence from EOAD studies highlight that the Aβ42 accumulation play a 
critical role during the progression of the disease. 
 
Unlike EOAD, the cause of LOAD is unclear with age being the greatest risk factor. In 
1993, the second major risk factor of LOAD was discovered to be APOε4 (Corder et al., 1993). 
APOE is generally involved in redistribution and mobilization of cholesterol with three different 
isoforms of APOEε2, 3, and 4. APOε4 is carried by 15-20% of LOAD patients. Individuals who 
are homozygous for the gene can have as high as 50% risk of displaying symptoms by mid to 
late 60s where as individuals who are heterozygotes can have as high as 50% risk displaying 
symptoms by mid to late 70s (Tarawneh & Holtzman, 2012). The exact contribution of APOε4 is 
unclear, but potential contributions include reduction in Aβ42 clearance and disruption of the 
brain blood barrier (BBB) that leads to leaky BBB (Scheltens et al., 2016). Interestingly, APOε4 
has been also characterized to influence tau pathogenesis and neuroinflammation independent of 
Aβ pathology. Briefly, tau P301S transgenic mice crossed with APOε4 knock-in mice showed 
significantly higher tau levels, great mislocalization of tau, greater brain atrophy and 
neuroinflammation compared to tau P301S transgenic mice crossed with APOε2 or APOε3 
knock-in mice (Shi et al., 2017). Therefore, APOε4 may be contributing to multiple aspects of 
AD disease progression. 
 
With the advent of genome-wide association study (GWAS), numerous genes have been 
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highlighted to be associated with the disease. These include genes involved in inflammatory and 
complement cascade, such complement receptor 1, CD33, and TREM2, endosomal APP 
processing, such as SORL1, BIN1, and PICALM, as well as various metabolic pathways 
(Lambert et al., 2013; Rogaeva et al., 2007; Scheltens et al., 2016).  
 
Despite the different causes, there are some striking clinical and pathological similarities 
between the two types of AD. Similar to EOAD, LOAD is characterized by the significantly 
increased production of Aβ42, suggesting that the Aβ42 accumulation is a common mechanism 
for both types of AD. Various AD mouse models that overexpress the EOAD associated 
mutations display increased Aβ42 production and age-dependent cognitive defects similar to 
symptoms characterized in sporadic AD patients. With the deeper understanding of the genetic 
cause of EOAD and the similarities between EOAD and LOAD disease progression, mutations 
of EOAD are used to model and study the more common LOAD (Nunan & Small, 2000).  
 
1.1.3 Models to study AD 
Many of the pathological processes recognized in the field have been identified using 
various AD models including transgenic animal models. Because the genes associated with 
EOAD are either components of or contributing to the formation of the plaques and NFTs, many 
hypothesized that the proteins that make up the aggregates are playing a causal role in the disease 
progression. Many of the transgenic mice that express APP mutations have become the most 
widely used models to study AD as they encapsulate the plaque pathology as well as memory 
impairment behavioral tests (Gotz & Ittner, 2008). 
One of the commonly used AD mouse model include the J20 mice, which overexpresses 
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APPSWE and APPIND driven by a strong PDGF-β promoter. These mice display many of the 
characteristics observed in sporadic AD patients including increased Aβ42 levels starting as early 
as 6 weeks, reduced CA1 pyramidal neurons (PNs) from 12 weeks, deficits in long-term 
potentiation (LTP) at the Schaffer’s Collateral-CA1 synapse starting from 3 months, and amyloid 
plaque formation at around 5-7 months (Hong, Beja-Glasser, et al., 2016; Mucke, Maslia, et al., 
2000; Pozueta et al., 2013). These mice also display behavioral changes that characterize the 
disease, such as spatial reference memory deficiency tested by radial arm maze and the Morris 
water maze (I. H. Cheng et al., 2007; Wright et al., 2013). Because the pathological and 
behavioral progressions of these mice are similar to those observed in sporadic AD patients, the 
J20 mouse model is one of the in vivo models used to study AD. It is important to note that this 
mouse model does not display any NFT and therefore is not the perfect model to study AD 
(Mucke, Maslia, et al., 2000). Another commonly used AD mouse model include the 5X familial 
form of AD mutant (FAD) transgenic mice, which APP gene with Swedish (K670N/M671L), 
Florida (I716V), and London (V717I) mutations and PS1 genes with M146L and L286V 
mutations are overexpressed (Oakley et al., 2006).  
 
In vitro models of AD have also provided valuable insight of the disease. One method is 
to use primary excitatory PN cultures to study how neurons respond to different mutations or 
different species of Aβ42 (Mairet-Coello et al., 2013). Again, it is important to note that this is 
not a perfect model to study AD. Therefore, many of the phenotypes of AD highlighted in the 




1.2 Cellular phenotypes observed in AD 
 1.2.1 Amyloid cascade hypothesis and synaptotoxicity 
The buildup of amyloid plaque occurs primarily before cognitive deficits. Even before 
the formation of amyloid plaques and NFT, amyloidogenic processing of APP by β- and γ-
secretase produces abnormal accumulation of Aβ42 peptide. Aβ42 peptides are more 
hydrophobic compared to the shorter species of Aβ and have a strong ability to oligomerize to 
form dimers, trimers, and higher order oligomers that ultimately fibrillate to form Aβ plaques 
(Sheng, Sabatini, & Sudhof, 2012). Oligomeric forms of Aβ42 (Aβ42o) lead to early loss of 
glutamatergic, excitatory synapses (synaptotoxicity) in cortical and hippocampal PNs starting 
before plaque formation (Figure 3), strongly suggesting that synaptotoxicity is an early event in 
the disease progression triggered by soluble Aβ42o (Hong, Beja-Glasser, et al., 2016; Mairet-
Coello et al., 2013; Masliah et al., 2001; Moolman, Vitolo, Vonsattel, & Shelanski, 2004; 
Shankar et al., 2007). This phenotype has been also observed in various AD mouse models 
including the J20 transgenic mouse model, where progressive loss of excitatory synaptic 
connections occur before Aβ plaque formation (Jacobsen et al., 2006; Mairet-Coello et al., 2013; 
Mucke, Maslia, et al., 2000). Soluble Aβ42o extracted biochemically from AD patients or 
produced synthetically also lead to rapid synaptic loss in PNs in vitro (Jin et al., 2011; Lacor et 
al., 2004; Lacor et al., 2007; Mairet-Coello et al., 2013; Shankar et al., 2007; Shankar et al., 
2008). The loss of excitatory synapses is now best correlated with the cognitive impairments of 
AD patients, and it is recognized as a strong quantitative neuropathological event. Many labs 
have collectively illustrated that the Aβ42 oligomers cause synaptic structural and functional 
changes, leading to the emergence of the amyloid cascade hypothesis where Aβ42 generation is 
primary and critical to the pathology during the early stages of AD (DeKosky & Scheff, 1990; 
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DeKosky, Scheff, & Styren, 1996; Serrano-Pozo et al., 2011; Terry et al., 1987; Terry et al., 
1991). 
 
Excitatory synaptic transmission is essential to many of integrative function of the brain, 
including in synaptic plasticity during adulthood. Most excitatory synapses have a mix of 
different metabotropic and ionotropic receptors. Two of the most extensively studied inotropic 
receptors with their fast neuronal excitation characteristics include α-amino-3-hydroxy-5-methyl-
Figure 3. Oligomers of Aβ, but not monomers, lead to synaptotoxic effects in 
hippocampal PNs. (A) Aβ monomers and oligomers were isolated from 
conditioned media (CM) of Chinese hamster ovary cells that overexpress 
hAPPIND mutation. Monomers and low oligomeric species were isolated from 
CM using size exclusion chromatography and ran on non-denaturing gel pre and 
post incubation in organotypic rat hippocampal slices to demonstrate no 
significant changes in the monomeric and oligomeric species. T= Trimers; 
D=Dimers; M=Monomers. (B) Representative images of organotypic 
hippocampal slice cultures treated with Aβ monomers or Aβ dimers for 5, 10, 15 
days. Apical dendrites were imaged. Scale bar, 5µm. (C) Quantification of spine 
density and spine length of figure 1.3B. *p<0.05 compared to control for each of 
the treatment condition. Figure is adapted from (Shankar et al., 2007). 	
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4-isoxazole propionate receptors (AMPARs) and N-methyl-D-aspartate receptors (NMDARs), 
which have been studied in both healthy and disease states (Nakanishi, 1994). AMPAR display a 
faster rise and subside of current, determining the onset as well as the maximal amplitude of 
excitatory postsynaptic current (EPSP). On the other hand, NMDAR respond with a slower rise 
and fall of current, determining the decay of EPSC (Iacobucci & Popescu, 2017). The evidence 
for Aβ42o reducing the number of glutamatergic synapses has not only been shown through 
structural changes in spine density, but also changes in electrophysiology properties suggesting 
that both NMDAR and AMPAR reduction occurs (Mairet-Coello et al., 2013; Malinow, 2012). 
Because many pharmacological studies have highlighted the important contribution of NMDAR 
in Aβ42o mediated synaptotoxicity, the dynamics of NMDAR in AD is discussed further below. 
 
Aβ42o can depress synaptic transmission in both a cell-autonomous and non-cell 
autonomous manner. Work from the Malinow group elegantly illustrated that neurons 
overexpressing APPSWE by viral transfection leads to synaptic reduction cell-autonomously as 
well as on nearby wildtype neurons that are not transfected (Kamenetz et al., 2003). Currently, it 
has been hypothesized that Aβ42o released from both the dendrites and axons can have 
synaptotoxic effects. Overexpressing APPSWE in just the CA3 PNs resulted in synaptotoxic 
effects in both CA3 and CA1 PNs, suggesting the Aβ42o released from the axons of CA3 PNs 
that synapse onto CA1 PNs were sufficient to cause toxicity in CA1 PNs. Using pharmacological 
inhibitor of NMDAR, (2R)-amino-5-phosphonovaleric acid (AP5), led to protective effects 
against Aβ42o mediated synaptotoxicity and impaired LTP, highlighting the role of NMDAR 
upon Aβ42o stress (Wei et al., 2010). Hyperactivation of NMDAR upon acute treatment of 
Aβ42o is thought to result in excessive Ca2+ influx and excitotoxicity (discussed in the next 
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section) before the reduction of synapse density. The current hypothesis is that blocking 
NMDAR dependent Ca2+ influx by Aβ42o can protect some of the downstream effects of Aβ42o 
(Paoletti et al., 2013). Interestingly, neuronal activity itself has been shown to drive Aβ42o 
production, suggesting a negative feedback loop function of Aβ42o upon neuronal activation. 
Pharmacological blockage of neuronal activity using tetrodotoxin, high Mg2+, and gamma-
aminobutyric acid (GABA) A receptor activator led to reduction of Aβ oligomers levels, whereas 
increasing neuronal activity, using picrotoxin to inhibit GABAR, increased Aβ oligomer species. 
The current hypothesis is that Aβ processing and/or secretion is in part activity-dependent and 
can have a feedback loop response to the hyper-excitability observed during the early stages of 
AD (Kamenetz et al., 2003). 
The role of NMDAR in driving Aβ42o mediated synaptotoxicity led to the development 
of memantine as a method of treatment for AD. Memantine is mainly used as NMDAR channel 
blocker, but as mentioned before, the effects are mild and only observed in very small number of 
patients for unclear reasons (Paoletti et al., 2013). Some of the uncertainties stem from lingering 
questions about the exact dynamics of NMDAR during the disease progression. NMDAR are 
hetero-tetramers composed of various subunit compositions. It is unclear if all or selective 
subunits are involved in driving the Ca2+ influx upon Aβ42o treatment or if there are specific 
conformational changes of NMDAR. Another interesting question is whether tau contributes to 
NMDAR dynamics, as hyperphosphorylation of tau is the second key player along with Aβ42o 
in AD progression. Previous studies have highlighted that tau, localized in the axons under 
physiological conditions, can mislocalize to dendrites upon hyperphosphorylation. One study 
proposes a mechanism for the hyperphosphorylated tau dependent NMDAR disruption. 
Mislocalization of hyperphosphorylated tau can result in the transport of Fyn kinase to spines, 
 15	
which can phosphorylate the NMDAR subunit NR2. This posttranslational modification results 
in a stronger interaction between NR2 and postsynaptic density protein 95 (PSD95) that results 
in excitotoxicity by NMDAR (Ittner et al., 2010). Another group suggested that this mis-
localization is ultimately associated with removal of NMDAR from synapses (Hoover et al., 
2010) (Figure 4). Therefore, a deeper understanding of the NMDAR dynamics and disruption 
during the early stages of AD and through the disease progression is needed to develop a more 
specific therapeutic approach. However, what has been long supported is that the spine loss upon 
Aβ42o exposure occurs in excitatory PNs during the early stages of AD upstream of tau.  
 
1.2.2 Excitotoxicity and defects of intracellular Ca2+ homeostasis  
Ca2+ plays a critical role as a second messenger in neurons, including presynaptic vesicle 
fusion and neurotransmitter release, postsynaptic signal transmission, and many Ca2+-dependent 
signaling pathways. Under physiological conditions, neurons have very low intracellular Ca2+ at 
10-100nM range whereas depolarization can lead to increase of intracellular Ca2+ to lower µM 
range (Simms & Zamponi, 2014). Ca2+-dependent signaling regulates various forms of activity-
dependent gene transcription, neurotransmitter release, long-term synaptic plasticity in part by 
regulating Ca2+/calmodulin-dependent kinase (CAMKII), calcineurin (Ca2+ dependent 
phosphatase), and protein kinase C (Kwon, Hirabayashi, & Polleux, 2016). However, prolonged 
increase in intracellular Ca2+ can be cytotoxic and has been linked with various neurological 
disorders. Therefore, there is a tight spatial and temporal regulation of Ca2+ concentration in 
neurons (Simms & Zamponi, 2014). 
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Neurons tightly regulate the intracellular Ca2+ concentration through various 
transmembrane exchangers and pumps as well as through various intracellular organelles. 
Baseline Ca2+ levels can be regulated by transmembrane proteins that can extrude Ca2+ to the 
extracellular space including Ca2+-ATPase, Na2+/Ca2+ exchanger and Na2+/Ca2+-K+ exchanger. 
NMDAR and voltage-gated Ca2+ channels (VGCC) serve as the main receptors for Ca2+ to enter 
Figure 4. Understanding the dynamics and changes of NMDAR upon Aβ42o 
exposure. Cartoon illustrating potential dynamics of NMDAR upon exposure to 
Aβ42o. Aβ42o is thought to initially cause NMDAR dependent Ca2+ influx leading 
to increased excitotoxicity. Aβ42o has also been shown to mislocalize 
hyperphosphorylated tau into spines, recruiting a specific Fyn kinase that can 
phosphorylate the NR2 subunit of NMDAR. Upon phosphorylation, NR2 
increases its interaction with PSD95 that drives higher excitotoxic effects. It is 
hypothesized that neurons are desensitized and respond by endocytosizing 
NMDAR, ultimately resulting in reduction of synapses (Paoletti, Bellone, & Zhou, 
2013). 
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from the extracellular space. Intracellular organelles including mitochondria and endoplasmic 
reticulum (ER) also contribute to Ca2+ regulation. Mitochondria play a role in buffering 
intracellular cytoplasmic Ca2+ via the mitochondria uniporter (MCU). ER is a well-known 
internal store that can sequester up to ~500 µM range via ER Ca2+-ATPase (SERCA) and store-
operated Ca2+ entry (SOCE). ER can also release Ca2+ into the intracellular compartment in 
activity dependent manner. NMDAR and VGCC dependent Ca2+ influx leads to ER release via 
Ca2+ induced Ca2+ release (CICR) in part via ryanodine receptors (RyR) whereas metabotrophic 
glutamate receptor activation can activate phospholipase C to produce inositol triphosphate (IP3) 
to trigger inositol triphosphate 3 induced Ca2+ release (IICR) from the ER (Simms & Zamponi, 
2014). However, disruption of this intricate Ca2+ regulation has been observed in various AD 
models and associated with excitotoxicity as outlined below. 
 
Along with the synaptotoxic effects by Aβ42o, an early phenotype is disruption in 
calcium homeostasis in various AD mouse models. Ca2+ transient, reflecting the endogenous 
activity of PNs, is disrupted in different AD mouse models. Work from the Konnerth lab has 
shown that there is a significant increase in the fraction of both hyper- and hypo-active neurons 
and corresponding reduction in the fraction of neurons showing ‘normal’ range of activity in the 
visual cortex using 2-photon Ca2+ imaging. In the study, the authors use the APP25 x PS45 
transgenic mouse model that overexpresses APPSWE mutation as well as PS1 G384A mutation. 
At 8 months of age, PNs were categorized as normal, hypoactive, and hyperactive if their Ca2+ 
transients showed 0.25-4, <0.25, and >4 frequencies/min, respectively. In this AD mouse model, 
the authors reported a significant reduction of normal and increase in both hypoactive and 
hyperactive PNs in the visual cortex. Treatment of GABA receptor antagonist, gabazine, led to 
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restoration of orientation tuning only on hypoactive PNs, but not in hyperactive PNs, suggesting 
that hyperactive PNs undergo intrinsic changes that dramatically contribute to disruption at 
circuitry level (Grienberger et al., 2012). The same APP25 X PS45 mouse model at early stages 
(~6-7 months) also displays disruption of spontaneous activity in CA1 PNs. The authors report 
there is an increase of both hypo and hyperactive neurons, but hyperactive neurons were 
selectively located near amyloid plaques. When examining the mice before plaque formation, 
majority of the transgenic mice show increase of hyperactive neurons rather than hypoactive 
neurons, a clear sign of hyper-excitability. It is interesting to note that during the early stages 
before plaque formation, hippocampal PNs display disrupted Ca2+ transients whereas cortical 
PNs do not. Only after initiation of plaque formation does cortical PNs display abnormal 
spontaneous activity, in line with the hypothesis that the hippocampus is one of the most primary 
regions affected by AD (Busche et al., 2012).  
 
Various studies have also illustrated that there is an increase in resting Ca2+ levels in the 
soma of PNs due to oligomeric species of Aβ. Using in vitro cell culture models, synthetic 
oligomeric Aβ42 has been shown to rapidly increase intracellular Ca2+ (Demuro et al., 2005; Guo 
et al., 1999). Work primarily from the Bacskai’s laboratory examined various AD mouse models 
to study intracellular Ca2+ using a ratiometric calcium sensor YC3.6. Layer 5 cortical PNs were 
studied in wildtype mice as well as APPSWE/PS1 ΔE9, APPSWE, PS1 M146V, and PS1 ΔE9, 
mice. Compared to wildtype cortical PNs, mice that contained APP mutations showed a dramatic 
increase in the intracellular Ca2+ concentration at older ages. Interestingly, the authors show that 
cytoplasmic Ca2+ overload correlated with morphological changes. While wildtype PNs showed 
spino-dendritic calcium compartmentalization, APP mutants displayed loss of this 
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compartmentalization of Ca2+ concentration (Kuchibhotla et al., 2008). Only the mutants that 
showed Ca2+ overload exhibited morphological changes of aspiny and beaded dendrites, strongly 
suggesting that only PNs that experience calcium dysregulation actual undergo morphological 
changes (Kuchibhotla et al., 2008). This led to the hypothesis that Ca2+ dysregulation occur 
before the synaptic loss during the early stages of AD.  
 
  Follow up study from the Bacskai’s group also highlight that oligomeric species of Aβ is 
causal to the Ca2+ dysregulation (Arbel-Ornath et al., 2017). Using the ratiometric calcium sensor 
YC3.6, intracellular Ca2+ levels of somatosensory cortex were examined upon acute injection of 
oligomeric Aβ in 3-6 month old healthy mice. Naturally occurring soluble oligomeric Aβ was 
obtained from conditioned media of transgenic primary neuronal culture. When healthy mice 
were injected with conditioned media from wildtype PNs, resting Ca2+ concentration was tightly 
around 70nM, whereas mice injected with conditioned media containing oligomeric Aβ species 
showed significant increase of around 10-20% in the soma (Arbel-Ornath et al., 2017). 
Altogether, oligomeric species of Aβ drive the Ca2+ disruptions observed in excitatory PNs, 
which precedes the morphological spine changes. This idea is further supported by subclinical 
incidences of epilepsy in non-demented carriers of APOε4 and around 40% of young patients 
with sporadic AD (Palop & Mucke, 2010).  
 
What is currently unresolved in the field however is the source of the intracellular Ca2+ 
increase following exposure to Aβ oligomers. There are at least two non-mutually exclusive 
sources for the Ca2+ built including (1) from synaptic origin via NMDAR and VGCC, (2) from 
intracellular Ca2+ stores such as the ER and/or lack of mitochondrial uptake. Much of what we 
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understand about Ca2+ homeostasis in neurons stems from pharmacological studies (which has 
limitations due to their varying potency and off target effects) in order to examine the role of 
various channels. Inhibitors of VGCC and NMDAR, such as nifedipine, conotoxin, and MK801, 
have been shown to block Ca2+ dysregulation in vitro upon acute oligomeric Aβ treatment 
(Arbel-Ornath et al., 2017). In line with this, using APPSWE x PS1G384A transgenic mice that 
display Ca2+ dysregulation in hippocampal PNs, treatment with ionotropic glutamate receptor 
inhibitors such as 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), AP5, and MK801 can restore 
the abnormal frequency of Ca2+  transients (Busche et al., 2012; Lerdkrai et al., 2018). However, 
the role of ER in Ca2+ dysregulation is still under debate. In vitro models suggest use of 2-
Aminoethoxydiphenyl borate (2-APB) to block IP3R or dantrolene to block RyR did not rescue 
Ca2+ dysregulation (Arbel-Ornath et al., 2017). However, using cyclopiazonic acid (CPA) that 
blocks ER Ca2+ ATPase and dantrolene in APPSWE x PS1G384A transgenic mice can restore the 
Ca2+ dysregulation, suggesting intracellular Ca2+ store might participate in the Ca2+ dysregulation 
phenotypes (Lerdkrai et al., 2018). One explanation for the potentially contradictory role of ER 
in Ca2+ dysregulation is that the different rescue effects may be due to the specific AD models 
and/or to the unspecific effects of these pharmacological drugs as well as the lack of cellular 
specificity (affecting pre-, postsynaptic neurons as well as astrocytes). Thus, a more extensive 
study is necessary to illustrate the contributions of both intracellular and extracellular source of 
Ca2+ and the exact mechanism behind how intracellular Ca2+ builds up in AD. Although the 
source of Ca2+ is still under debate, what is clear is that the buildup of Ca2+ in neurons leads to 
changes in various Ca2+ dependent-signaling pathways that are highlighted in section 1.3.1.  
 
1.2.4 Mitochondrial dynamics in healthy and AD conditions 
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 Mitochondria are key cellular organelles that are characterized by double membrane 
morphology with various metabolic functions, such as adenosine triphosphate (ATP) generation, 
phospholipid biogenesis, amino acid production, Ca2+ buffering, iron-sulfur cluster biogenesis, 
and cell death signaling (Pickles, Vigie, & Youle, 2018). The inner mitochondrial membrane 
(IMM) encloses the matrix space and folds to make cristae, where the electron transport chain 
(ETC) complex is found. Enclosing the IMM as well as the intermembrane space is the outer 
mitochondrial membrane (OMM) (Youle & van der Bliek, 2012). Mitochondria are unique in 
that they contain their own small, circular 16-kbp genome that encodes subunits of the ATP 
synthesis and ETC proteins as well as transfer and messenger RNAs. This genetic information is 
often found in protein-rich complexes called nucleoids. Mitochondria lack nucleotide excision 
repair machinery and due to the unavoidable byproduct of ETC, reactive oxygen species (ROS), 
mtDNA mutations appear at higher frequencies with aging (D. C. Chan, 2006; Michikawa, 
Figure 5. Understanding mitochondrial fission and fusion. Mitochondria can 
undergo both fission and fusion events. (A) Mitochondrial fission includes proper 
recruitment of the GTPase, Drp1, onto the outer mitochondrial membrane and 
constriction of the organelle to produce two entities. (B) Mitochondrial fusion requires 
a concerted fusion of both IMM and OMM. OMM fusion is first mediated by Mfn1/2 
followed by OPA1 mediated IMM fusion (Cai & Tammineni, 2016). 
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Mazzucchelli, Bresolin, Scarlato, & Attardi, 1999). In healthy, physiological conditions, 
however, mitochondria have multiple protective mechanisms to ensure ROS does not build up to 
high levels. One line of defense is various degrading process to get rid of mitochondrial proteins 
that contribute to ROS generation. Mitochondria contain their own proteases to degrade proteins 
in the IMM. The OMM proteins can be removed by ubiquitin-dependent proteasome. Lastly, a 
bulk of mitochondria can be degraded through autophagy. Second line of defense is through 
mitochondrial antioxidant enzymes such as mitochondrial iron/manganese superoxide dismutase 
(SOD2) (D. C. Chan, 2006; Youle & van der Bliek, 2012).  
 
The very dynamic nature of mitochondria was observed dating back to 1914 when 
analysis of live chick embryonic cells showed that mitochondrial ‘granules’ can also form rods 
and chains that again break down to granules (M. R. Lewis & Lewis, 1914). Follow up studies 
have illustrated that different cell types can have various mitochondrial morphology and 
dynamics. For example, fibroblasts show long mitochondria with >10µm in length whereas 
hepatocytes are composed of more spherical mitochondria. Many of the cell types contain 
dynamic mitochondrial network, in large part, due to the changing balance of fission and fusion 
(Figure 5), mediated by various guanosine triphosphatases (GTPases) (Youle & van der Bliek, 
2012). 
 
 Because of the double membranous structure of mitochondria, there are unique OMM 
and IMM fusion proteins, all of which are members of the membrane anchored dynamin family. 
The OMM fusion is mediated by mitofusin 1 and 2 (Mfn1/2) proteins, which form homo-
oligomeric and hetero-oligomeric complexes, whereas the IMM fusion is mediated by optic 
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atrophy protein 1 (Opa1) (Youle & van der Bliek, 2012). Opa1 contains a trans-membrane 
domain with coil-coil segment, which allows homo-polymerization that is critical to tether 
opposing membranes to remodel cristae (Burte, Carelli, Chinnery, & Yu-Wai-Man, 2015). OPA1 
mediated IMM fusion can be sufficient for mitochondrial matrix contents to mix (Karbowski et 
al., 2004), where as OPA1 null MEFs display mitochondrial fragmentation as well as 
disorganization of cristae structures (D. C. Chan, 2006). Multiple groups have illustrated that 
fusion of IMM and OMM can be separated in part because Mfn null MEFs are devoid of both 
OMM and IMM fusion, whereas OPA1 null MEFs are only devoid of IMM. (Malka et al., 2005; 
Meeusen et al., 2006; Song, Ghochani, McCaffery, Frey, & Chan, 2009). 
 
In contrast to mitochondrial fusion, mitochondrial fission is mainly mediated by one 
dynamin-family member called dynamin-1-like protein (Drp1), a small GTPase residing in the 
cytosol that is recruited to the OMM for mitochondrial constriction/fission. In mammals, there 
are multiple adaptor proteins localized to the OMM that are identified to recruit Drp1, including 
mitochondrial dynamics protein 49 and 51 (Mid49 and Mid51), fission 1 (Fis1) and 
mitochondrial fission factor (MFF) (Youle & van der Bliek, 2012). There are conflicting results 
as to which adaptors are most important for Drp1 recruitment. For example, Fis1 knockout (KO) 
results in failure of Drp1 recruitment and therefore mitochondrial fission in yeast. However, 
contradicting results have been obtained in mammalian cells where knockdown of Fis1 in some 
cells have little effect on mitochondrial morphology, suggesting Fis1 might be functionally 
redundant with other Drp1 ‘receptors’ or may have a cell- and condition-specific function (D. C. 
Chan, 2006). On the other hand, MFF has been illustrated to be an effective Drp1 recruiter as 
knockdown of MFF reduces Drp1 localization on the OMM and MFF overexpression leads to 
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increased Drp1-dependent mitochondrial fission. MFF and Drp1 have also been shown to 
physically associate with each other, and MFF dependent fission has been shown to be Fis1 
independent (Otera, Miyata, Kuge, & Mihara, 2016).  
 
 Interestingly, mitochondrial fission has also been shown to couple with apoptosis. 
During apoptosis, BCL2 associated x protein (BAX) localizes to the OMM and colocalizes with 
Drp1. Ultimately, mitochondria membrane becomes permeable, allowing cytochrome c to 
release from the matrix to the cytosol in order to activate the caspase complexes. Interestingly, 
Figure 6. Examining the dynamics of mitophagy. Cartoon illustrating PINK1 and 
Parkin dependent mitophagy. (A) Upon mitochondrial stress or build up of damaged 
mitochondria, PINK1 accumulates on the OMM and phosphorylates ubiquitinated 
OMM proteins as well as Parkin. Accumulation of PINK1 and ubiquitinated proteins on 
the OMM recruits Parkin, which further adds ubiquitin to mark the mitochondria. (B) 
The build up of phosphorylated ubiquitin chain on the OMM recruits specific 
mitophagy receptors, OPTN and NDP52, that ensure proper recruitment of 
mitochondria to the growing phagophore and therefore the autophagy process (Matsuda 
& Tanaka, 2015). 
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Drp1 has been illustrated to function in BAX oligomerization on the OMM (Montessuit et al., 
2010), suggesting mitochondrial dynamics can influence various signaling pathways.  
 
 One of the mechanism of mitochondrial quality control include degradation of damaged, 
old, or unwanted mitochondria through autophagy and specifically in this case, mitophagy. The 
best-characterized type of mitophagy is the PTEN-induced putative kinase 1 (PINK1) and Parkin 
dependent mitophagy. Parkin is an E3 ubiquitin ligase downstream of PINK1. PINK1 selectively 
builds on the OMM of damaged mitochondria, often those with depolarized membrane potential. 
Its build up recruits and activates Parkin that ultimately leads to a reaction of ubiquitin chains to 
form, which are further phosphorylated by PINK1. These phospho-ubiquitin chains on the OMM 
are thought to recruit autophagy machinery, including specific mitochondrial adaptors that allow 
proper recruitment of mitochondria to the autophagy pathway (Burman et al., 2017). The 
specifics of autophagy pathway are discussed in section 1.2.5, but the specific mitophagy 
receptors are discussed here. Five different adaptors have been proposed for mitophagy: p62, 
neighbor of BRCA1 gene 1 (NBR1), nuclear domain 10 protein 52 (NDP52), optineurin 
(OPTN), and Tax1 binding protein 1 (TAX1BP1). Work from the Youle lab elegantly illustrated 
that mammalian cell lines are primarily dependent on NDP52 and OPTN following PINK1-
Parkin activation for proper mitophagy (Lazarou et al., 2015) (Figure 6). However, the essential 
adaptor proteins may be cell-type and/or condition-dependent. Interestingly, mitochondrial 
fission has been associated with mitophagy. Dominant negative form of Drp1 has been shown to 
prevent mitophagy, highlighting that fission is necessary for mitophagy to occur (Twig, Elorza, 
et al., 2008; Twig, Hyde, & Shirihai, 2008).  
 
 26	
Mitochondria are not only dynamic in their morphology, but also in their trafficking 
throughout the cell. Trafficking of mitochondria is largely regulated by Miro and Milton, which 
transport mitochondria along microtubules by the microtubule-based motors, kinesin and dynein. 
Mitochondrial Rho-GTPase (Miro) contains 2 GTPase domains and 2 Ca2+ binding EF motifs, 
allowing detection of changes in Ca2+ levels to regulate its activity. It localizes to the OMM and 
can bind to Milton, large coiled-coil containing kinesin adaptor protein (D. C. Chan, 2006). 
Milton was first characterized in Drosophila where Milton mutation in the eye led to complete 
absence of mitochondria in axons of photoreceptors, whereas the soma contained 
morphologically normal mitochondria. Miro mutations in Drosophila are also characterized by 
disrupted mitochondrial trafficking. Since then, studies in various mammalian studies have 
supported the role of Miro and Milton in mitochondrial trafficking (Schwarz, 2013). 
 
Because of the post-mitotic and polarized characteristics of PNs, maintaining 
mitochondrial homeostasis is highly dependent on dynamic balance of fission/fusion, efficient 
mitophagy, and mitochondrial trafficking (Ashrafi & Schwarz, 2015; Schwarz, 2013). Unique to 
PNs is the compartmentalized morphology of mitochondria in the somatodendritic versus axonal 
areas that may allow the mitochondria to carry out localized functions of ATP production, Ca2+ 
buffering, and or various metabolic functions (Rowland, Irby, & Spirou, 2000; Shepherd & 
Harris, 1998). For example, in layer 2/3 excitatory PNs, dendritic mitochondria are long and 
tubular whereas axonal mitochondria are small and punctate, suggesting compartment specific 
functions of mitochondria (T. L. Lewis, Jr., Courchet, & Polleux, 2013). Axonal mitochondria 
have been implicated to function in both ATP synthesis and Ca2+ buffering. Recent studies show 
that only about 50% of presynaptic boutons are associated with mitochondria. Interestingly, 
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boutons devoid of mitochondria accumulate more Ca2+ upon repetitive action potentials, leading 
to more release of synaptic vesicles (SV) (Kwon, Sando, et al., 2016). This is in contrast to the 
idea that mitochondria are critical for local ATP production for synaptic release (Rangaraju, 
Calloway, & Ryan, 2014) as the presence of mitochondria actually reduces the probability of SV 
release (Kwon, Sando, et al., 2016; Vaccaro, Devine, Higgs, & Kittler, 2017). Despite the large 
proportion of mitochondria residing in the dendrites, their specific functions have been less 
studied. However, mitochondria have been implicated in dendritic development. Work from the 
Sheng lab illustrated that mitochondria protruding to the spines decrease with neuronal 
maturation in vitro and increase with repetitive depolarization, highlighting that mitochondrial 
dynamics correlate with dendritic development and activity (Li, Okamoto, Hayashi, & Sheng, 
2004). However, more recent evidence using serial EM reconstructions suggest that the fraction 
of mitochondria protruding into dendritic spines is extremely low in vivo in cortical pyramidal 
neurons (for example 3/1,425 spines examined contain mitochondria) (Kasthuri et al., 2015) 
raising doubts on whether or not mitochondrial invasion of spines is occurring under 
physiological conditions. 
 
 More recent work from the Kittler laboratory elegantly shows the importance of 
mitochondrial trafficking in dendritic development and complexity (Lopez-Domenech et al., 
2016). The authors use Miro1 KO to examine alteration of mitochondrial trafficking in PNs. 
Miro1 deletion led to altered dendritic development in vitro and in vivo. Conditional Miro1 KO 
in postnatal CA1 hippocampal PNs showed that distal dendrites at 4 months had decreased 
mitochondrial density with no change in dendritic complexity. At 8 months, these mice showed 
reduced apical and dendritic lengths, displaying neurodegenerative phenotypes. Altogether, the 
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authors demonstrate that mitochondrial homeostasis is critical for both dendritic development 
and complexity (Lopez-Domenech et al., 2016).   
 
In AD, disruptions of mitochondrial morphology and maintenance have been reported 
previously. Firstly, altered levels of mitochondrial fission and fusion proteins have been 
observed in both AD mouse model and post-mortem AD patient brain samples. Addition of Aβ-
derived diffusible ligand (ADDLs) to immature PNs can lead to mitochondrial fragmentation in 
neurites and altered spine dynamics (Wang, Su, Lee, et al., 2009; Wang et al., 2008). Post-
translational modification of S-nitrosylation on Drp1 has been observed in AD patients and is 
thought to increase mitochondrial fission (Cho et al., 2009). Various groups have reported that 
Aβ can directly interact with mitochondrial proteins including Aβ binding alcohol 
dehydrogenase, cytochrome oxidase, and α ketoglutarate dehydrogenase, which disrupts with 
proper functioning of mitochondria.  However, whether these interactions occur in physiological 
conditions are still under debate (Lin & Beal, 2006). The Klann lab has also elegantly illustrated 
interesting relationship between ROS production and synaptic dysfunction. Overexpression of 
SOD2 in different AD mouse models has been shown to reduce Aβ deposition and prevent 
memory deficits (Dumont et al., 2009; Massaad, Pautler, & Klann, 2009; Massaad, Washington, 
Pautler, & Klann, 2009). A follow up study also illustrates that the LTP impairment can be 
prevented by mitochondrial-targeted antioxidant (MitoQ) and SOD/catalase mimetic, EUK134 
(Ma et al., 2011; Rong, Doctrow, Tocco, & Baudry, 1999; Smith & Murphy, 2010). MitoQ can 
actually reduce ROS generated by mitochondria and prevent LTP impairment characterizing 
these AD mouse models, linking mitochondrial disruption with synaptic failure observed in AD. 
Lastly, more recent study shows that mitochondria-on-a-string (MOAS) phenotype has been 
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observed broadly in the CA1 region, without cell specificity, in various AD mouse models and 
AD patients (Zhang et al., 2016). However, the biological role that mitochondria play in disease 
progression in vivo, especially in relation to synaptotoxicity, remains unclear. Moreover, the 
molecular mechanism that can co-regulate both spine and mitochondrial toxicity remains 
unidentified.  
 
 1.2.5 Autophagy/lysosomal dynamics in healthy and AD conditions 
 In mammalian cells, there are two main mechanisms of degrading cytoplasmic contents. 
One is by the proteasomal dependent degradation where very specific cargos are ubiquitinated 
and targeted to the proteasome. The second method of degradation is via the lysosome where 
various substrates, including extracellular, cytoplasmic, and plasma membrane contents, can get 
degraded. One of the catabolic processes that rely on lysosomes is autophagy. Autophagy is an 
evolutionarily conserved, intracellular degradation system. It not only serves as a degradative 
system, but also as a recycling system to replenish new building blocks and energy. There are 
three types of autophagy: (1) macroautophagy, where intermediate organelles called 
autophagosomes (AP) are used to deliver material to the lysosomes, (2) microautophagy, where 
lysosomes can engulf material itself on cytosolic proteins tagged with KFERQ motif, and (3) 
chaperone mediated autophagy, where lysosomes rely on chaperones for proper target delivery 
(Mizushima & Komatsu, 2011). This thesis will focus mainly on macroautophagy that will be 
referred to as just autophagy from here and onwards.  
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 During the 1990s, genetics studies of yeast identified the first set of autophagy related 
Figure 7. Mechanism of autophagsome formation in mammalian cells. 
Cartoon illustrating key players of macroautophagy. In the presences of insulin 
growth factors or amino acids, mTORC1 is activated and blocks initiation of 
autophagy. ULK1 complex is composed of ULK1, Atg13, FIP200, and Atg101. 
This ULK complex is activated upon autophagy induction and translocates to the 
forming phagophore, where they regulate the phosphatidyninositoal 3 phosphate 
kinase (PI3K) complex composed of Beclin, Atg14L, Ambra1, PI3K, and vacuolar 
protein sorting (Vps) 15. The PI3K complex forms phophatidylinosital 3 
phosphate (PI3P) that interacts with double FYVE-contain protein (DFCP1) and 
WD-repeat protein interacting with phosphoinoside (WIPI), which contribute to 
formation and elongation of phagophore, respectively. Lastly, Atg12-Atg5-
Atg16L1 complex and the LC3/Atg8-conjugated to phosphatidylethanolamine 
(PE) contribute to elongation and closure (Mizushima & Komatsu, 2011). 
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(ATG) genes that are critical to autophagy. In yeast, 35 ATG genes have been identified with the 
core of the proteins conserved in eukaryotes (Harding, Morano, Scott, & Klionsky, 1995; 
Thumm et al., 1994; Tsukada & Ohsumi, 1993). Autophagy is essential for surviving starvation 
period as systemic deletion of Atg 5 and 7 in mice lead to death soon after birth with 
significantly reduced levels of amino acid during the neonatal starvation period (Komatsu et al., 
2005; Kuma et al., 2004). Follow up molecular and cellular studies have highlighted unique 
mechanism of autophagy as well as their functions. The mechanism of autophagy is highlighted 
in Figure 7. During nutrient rich conditions, autophagy is inhibited by a master metabolic 
regulator called mammalian target of rapamycin complex I (mTORC1). Autophagy is initiated 
under nutrient starvation or other stress conditions. Upon initiation, the Unc-51 like kinase (Ulk) 
1/2 complex, composed of Ulk1/2, Atg 13, family kinase-interacting protein of 200kDA 
(FIP200), and Atg 101, is formed and activated on site of AP formation (Mizushima & Komatsu, 
2011). AP generation has been shown to occur in close proximity to the ER, but the exact source 
of AP membrane component is still under debate (Hayashi-Nishino et al., 2009). Studies have 
suggested that AP membrane can initially derive from Golgi, mitochondria, and the plasma 
membrane (Hailey et al., 2010; Mizushima & Komatsu, 2011; Ravikumar, Moreau, Jahreiss, 
Puri, & Rubinsztein, 2010; Tooze & Yoshimori, 2010). The activated Ulk complex is then 
translocated to the forming phagophore where they regulate another complex called the 
phosphatidylinositol 3 phosphate kinase (PI3K) complex composed of Beclin, Atg14L, vacuolar 
protein sort (Vps) 15, Vps 34, and Ambra 1. These complexes are able to generate 
phosphatidylinositol 3 phosphate (PI3P), which recruits double FYVE- containing protein 
(DFCP1) involved in promoting phagophore formation. Other PI3P binding protein called WD- 
repeat protein interacting with phosphoinoside (WIPI) contribute to the elongation of 
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phagophore. And ultimately the Atg12-5-17L complex and Atg8/LC3-conjugated to 
phosphatidylethanolamine (PE) is involved in the elongation and closure to form the AP. As the 
AP elongates, cytoplasmic contents and or selected cargoes are recruited into the AP. APs then 
are fused with lysosome to form autolysosomes (ALs) where the contents are degraded due to 
the acidic pH of lysosomes as well as the various hydrolases present in lysosomes (Mizushima & 
Komatsu, 2011). 
 
 In the central nervous system (CNS), mice lacking autophagy by deletion of core 
components of autophagy machinery Atg 5 and 7 show neurologic deficits, including abnormal 
limb-clasping reflexes, lack of motor coordination, locomotors ataxia and significant loss of 
Purkinje cells in cerebellar and cerebral cortex (Hara et al., 2006; Komatsu et al., 2006). As 
Figure 8. Ultrastructural buildup of autophagic vacuoles in AD brain. (A) In 
brain samples of non-AD control patients, AVs are rarely observed in neuronal 
processes and synaptic terminals. (B) In brain samples from AD patients, AVs are 
relatively common in dystrophic neuritis as well as in (C) synaptic terminals, 
suggesting disruption of the autophagy pathway during AD (Nixon, 2005). 
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mentioned previously, neurons have unique cell biology due to their extreme morphological 
polarization and compartimentalization, which led neuronal cell biologists to ask how autophagy 
is regulated in PNs. Much of what is understood about autophagy in neurons is the result of 
studying autophagosome biogenesis and dynamics in axons for turnover of mitochondria (Maday 
& Holzbaur, 2012; Maday, Wallace, & Holzbaur, 2012; Y. C. Wong & Holzbaur, 2014), 
synaptic vesicle (Okerlund et al., 2017), and aggregated proteins (Ravikumar et al., 2010). 
Interestingly, AP formation primarily occurs in distal ends of axons of cortical, dorsal root 
ganglion, and hippocampal neurons (X. T. Cheng, Zhou, Lin, Cai, & Sheng, 2015; S. Lee, Sato, 
& Nixon, 2011; Maday & Holzbaur, 2012, 2014; Maday et al., 2012). The APs undergo dynein 
dependent retrograde transport towards the soma where en route, they fuse with lysosomes 
(Maday & Holzbaur, 2014), highlighting the unique dynamic of autophagy in neurons.  
 
 Mounting evidence has also implicated altered autophagy in the pathogenesis of AD as 
abnormal autophagic vacuoles (AV), including AP and AL, build-up in neurites of AD patients 
at least at the late stages of the disease progression as well as in various AD mouse models 
(Figure 8) (Nixon, 2005; Yu et al., 2005). Interestingly, AD genetics have also supported the 
hypothesis that autophagy may have a pathogenic failure in AD as mutations on PS1 disrupts the 
lysosomal proteolysis (Nixon & Yang, 2011). Conditional deletion of PS1 has been shown to 
increase abnormal accumulation of autophagy substrates in neurons along with impaired 
lysosome protein, cathepsin, activation (Esselens et al., 2004; J. H. Lee et al., 2010; Wilson et al., 
2004). Supporting this data, fibroblasts from EOAD patients with PS1 mutations also showed 
defective lysosomal acidification and AL maturation (J. H. Lee et al., 2010). However, at what 
step of autophagy is disrupted is still under debate. Increased autophagy induction has been 
 34	
implicated in part due to upregulation of proteins involved in lysosome synthesis (Cataldo et al., 
1995; Ginsberg et al., 2010). Supporting this idea, genome-wide studies using brains of AD show 
that transcription factors involved in promoting autophagy are upregulated, whereas the negative 
regulators of autophagy are downregulated (Lipinski et al., 2010). It is also possible that a 
combination of induction as well as degradative dysfunction occurs during the progression of 
AD (Nixon & Yang, 2011). 
 
1.2 Molecular Mechanisms underlying AD pathophysiology  
With the observation of these cellular phenotypes, there has been a concerted action to 
identify signaling pathways that can mediate one or multiple phenotype/s. Because the loss of 
spines has been well characterized as an early event and now best correlated with the cognitive 
impairments of AD patients (DeKosky & Scheff, 1990; Serrano-Pozo et al., 2011; Terry et al., 
1987; Terry et al., 1991), many labs have focused on identifying the molecular mechanisms 
behind Aβ42 induced synaptotoxicity. As previously introduced, Aβ42 induces increase in 
intracellular Ca2+ that activates Ca2+ dependent phosphatase β, calcineurin. Downstream of 
calcineurin, nuclear factor of activated T cells (NFAT) is also activated. Hyperactivation of 
calcineurin and NFAT has been shown to result in dystrophic neurites, dendritic simplification 
and spine loss in vitro and in vivo, whereas inhibition of the NFAT pathway has been shown to 
alleviate Aβ neurotoxicity in AD mice (Hudry et al., 2012; H. Y. Wu et al., 2010). Glycogen 
synthase kinase 3β has also been observed to be hyperactivated in various AD models. This 
serine/threonine kinase is generally involved in various metabolic pathways including glycogen 
metabolism, gene transcription, as well as apoptosis. When hyperactivated, GSK3β has been 
shown to lead to memory impairment, tau hyperphosphorylation, increase Aβ production, and 
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neuroinflammation, contributing to multiple aspects of AD pathogenesis (Hooper, Killick, & 
Lovestone, 2008). However, single therapeutic of GSK3β inhibition has shown conflicting 
outcomes, in part possibly because GSK3β can activate NFAT dependent apoptosis (Lei, Ayton, 
Bush, & Adlard, 2011). Other hyperactivated signaling molecules that have been shown to 
function in disrupted synaptic plasticity and synaptotoxicity include CDK5 and Caspase 2 with 
unclear downstream effectors and exact mechanism for spine loss (Mairet-Coello & Polleux, 
2014; Pozueta et al., 2013). Despite the identification of these molecular pathways as well as 
those not mentioned in this thesis due to space, there has yet to be a pathway that coordinates the 
multiple phenotypes of synaptotoxicity, Ca2+ dyshomeostasis, mitochondrial remodeling, 
autophagy dysfunction, and tau pathology. As part of this thesis, I characterized a novel kinase 
pathway that potentially unifies and coordinates these cellular phenotypes introduced below.  
 
1.3.1 Hyperactivation of CAMKK2-AMPK pathway in AD 
 As discussed above, disruption of neuronal intracellular, cytoplasmic Ca2+ dynamics by 
oligomeric Aβ42 is a cellular phenotype observed during the early stages of AD in various AD 
models. The Aβ42 induced Ca2+ increase has been shown to trigger various Ca2+ dependent 
signaling pathways, including the calcium/calmodulin kinase kinase protein 2 (CAMKK2) - 
AMP-activated kinase (AMPK) pathway that will be highlighted here. It is important to note that 
there have been several signaling pathways implicated in AD, but exactly how they all contribute 
to the progression of AD is unclear (Mairet-Coello & Polleux, 2014). What seems to be 
consistent is that the CAMKK2-AMPK pathway is a unique signaling pathway that is involved 
in multiple cellular phenotypes covered above throughout the progression of the disease. 
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Results from our lab as well as others demonstrated that Aβ42 over-activates AMPK in a 
CAMKK2 dependent manner and that inhibition of AMPK protects hippocampal neurons from 
Aβ42 mediated spine loss in vitro and against the loss of spines observed in the hAPPSWE, IND 
transgenic mouse model (J20) in vivo (Ma et al., 2014; Mairet-Coello et al., 2013; Son, Jung, 
Shin, Byun, & Mook-Jung, 2012; Thornton, Bright, Sastre, Muckett, & Carling, 2011). 
Figure 9. AMPK regulates various metabolic pathways via many 
downstream effectors. Upon activation under metabolic stress, AMPK is involved in 
regulating various pathways including lipid metabolism, protein metabolism, glucose 
metabolism, and autophagy and mitochondrial homeostasis. The arrows indicate 
whether AMPK phosphorylation activates or inhibits the function of downstream 
effectors (Herzig & Shaw, 2018). 
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CAMKK2 is a Ca2+ dependent serine/threonine kinase that acts as an upstream effector for 
calcium/calmodulin kinases, CAMKI and CAMKIV, as well as AMPK (Racioppi & Means, 
2012).  
 
AMPK is also a serine/threonine kinase composed of catalytic subunit (α1/α2), β adaptor 
subunit (β1/β2), and γ subunit (γ1, γ2, or γ3) that can be allosterically activated by AMP/ADP 
(Carling, Thornton, Woods, & Sanders, 2012; Mihaylova & Shaw, 2011). AMPK is best-
characterized as a metabolic sensor in non-neuronal cells where phosphorylation of T172 leads 
to its catalytic activation and functions in various metabolic pathways and mitochondrial and 
autophagy homeostasis (Figure 9) (Herzig & Shaw, 2018).  
 
In neurons, AMPK is activated upon increased Ca2+ levels and therefore acts not only as a 
metabolic sensor but also in response to neuronal activity (Mairet-Coello & Polleux, 2014; 
Thornton et al., 2011). Interestingly, AMPK is over-activated under various stress conditions 
such as ischemia, hypoxia, and glucose deprivation in neurons (Culmsee, Monnig, Kemp, & 
Mattson, 2001; Gadalla et al., 2004; Kuramoto et al., 2007; McCullough et al., 2005). Moreover, 
AMPK is primarily localized in the nucleus of PNs in non-AD brain samples, whereas in AD 
patients, catalytically active AMPK is abnormally accumulated in the cytoplasm of PNs of CA1, 
entorhinal/transentorhinal region, and cortex (Vingtdeux, Davies, Dickson, & Marambaud, 
2011). AMPK over-activation has been consistently reported in AD patient brain samples (Ma et 
al., 2014; Vingtdeux et al., 2011), in various AD mouse models (Ma et al., 2014; Mairet-Coello 
et al., 2013; Son et al., 2012), as well as in vitro upon acute treatment of oligomeric Aβ42 (Ma et 
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al., 2014; Mairet-Coello et al., 2013; Thornton et al., 2011; Yoon et al., 2012), which 
cumulatively highlight the relevance of this protein to AD.  
 
The CAMKK2-AMPK signaling pathway is unique in its involvement in multiple 
phenotypes observed during the progression of AD. The present study (see Chapter 2) and 
previous reports collectively implicate this signaling pathway as the first to unify multiple 
phenotypes reported in the brain of AD patients and in AD mouse models, including disruption 
of Ca2+ homeostasis, APP processing, tau phosphorylation, mitochondrial remodeling, increased 
autophagy, and synaptic loss (Nixon, 2005, 2013; Sheng et al., 2012). There is growing evidence 
that one of the earliest event upon Aβ42o application is disrupted cytoplasmic Ca2+ homeostasis 
that drives PNs hyperexcitability as discussed above (Arbel-Ornath et al., 2017; Busche et al., 
2012; Grienberger et al., 2012; Kuchibhotla et al., 2008; Lerdkrai et al., 2018; Palop & Mucke, 
2010). This increased Ca2+ accumulation precedes spine morphological changes (Arbel-Ornath et 
al., 2017), strongly suggesting that Ca2+-dependent signaling pathways, including the CAMKK2-
AMPK pathway, occur early in the disease progression and might play critical roles in reduction 
of synaptic plasticity and synaptic maintenance characterizing the early stages of AD (Hsieh et 
al., 2006; Malinow, 2012). Interestingly, Aβ42o-induced AMPK over-activation has been found 
to induce a vicious cycle of increased Aβ42o production via activation of JNK3-dependent APP 
processing (Yoon et al., 2012). Furthermore, AMPK links the two key players of AD: Aβ42o and 
tau. Catalytically active pAMPK has been shown to co-localize with phosphorylated-S262tau in 
brains of AD patients (Vingtdeux et al., 2011), and previous work from our lab as well as others 
highlights that hyperactivation of AMPK by Aβ42o leads to tau phosphorylation on its KxGS 
motifs – S262 and S356 (Mairet-Coello et al., 2013), which is thought to act as a priming site for 
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other phosphorylation sites (Waxman & Giasson, 2011). These results suggested the CAMKK2-
AMPK signaling pathway links Aβ42o to Tau, the two main drivers of synaptic loss (Ittner et al., 
2010; Mairet-Coello et al., 2013; Mairet-Coello & Polleux, 2014; Roberson et al., 2011; 
Roberson et al., 2007; Thornton et al., 2011).  
 
1.3.2 Downstream effectors of CAMKK2-AMPK pathway 
 Other downstream effectors of AMPK have been extensively studied in non-neuronal 
cells (Figure 9) and include those that maintain mitochondrial integrity such as mitochondrial 
fission factor (MFF) and Unc-51 like autophagy activating kinases 1/2 (ULK1/2 also called 
Atg1) (Egan et al., 2011; Toyama et al., 2016). As discussed above, MFF is an outer 
mitochondrial protein with two identified AMPK phosphorylation sites. Upon AMPK activation, 
MFF enhances the recruitment of the fission protein, Drp1, a step thought to be required for 
efficient mitophagy. Interestingly, in cells expressing MFF with serine to alanine mutations on 
the two AMPK phosphorylation sites (MFF AA), Drp1 localization is not dramatically altered 
compared to controls in basal condition. However, upon AMPK activation by metabolic stress, 
Drp1 fails to be further recruited by the MFF-AA mutant. Therefore, under metabolic stress, 
AMPK can modulate mitochondrial remodeling through its regulation via MFF (Toyama et al., 
2016).  
Another critical downstream effector of AMPK is the Ulk proteins. Ulk1 has multiple 
AMPK phosphorylation sites including at S555, S637, and S757 and functions in autophagy. 
AMPK can also indirectly activate autophagy by inhibiting mTORC1 complex, which inhibits 
autophagy under nutrient rich conditions. There are four isoforms of Ulk, but Ulk 1 and 2 are 
thought to be the main isoforms that can phosphorylate various effector proteins involved in 
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autophagy during the initial stages. The two isoforms are thought to have functional redundancy 
as both can interact with Atg13 and FIP200 and can have dominant negative effect upon 
overexpression of the kinase mutant form. Many of the cell lines studies have focused on 
characterizing Ulk1 (He & Klionsky, 2009; Kim, Kundu, Viollet, & Guan, 2011; P. M. Wong, 
Puente, Ganley, & Jiang, 2013). However, when examining gene expression of the two isoform 
in mouse embryos, Ulk2 is highly expressed in the CNS compared to Ulk1 (Figure 10). In situ 
hybridization of 8-week-old mice also highlight that Ulk2 mRNA is more highly expressed than 
Ulk1 in brain sections (Joo et al., 2016). Therefore, Ulk2 seems to be the main isoform in the 
CNS, potentially explaining the mild phenotypes observed in the CNS of Ulk1 knockout mice (P. 
M. Wong et al., 2013). Moreover, whether the downstream effectors of AMPK, MFF and Ulk2, 
may a role in AD remained unknown. If these proteins do play a role, it not only serves as a 
novel player in AD, but could also shed light in the causal relationship between various cellular 
phenotypes of AD and my thesis work more specifically tested if over-activation of CAMKK2-













Figure 10. Gene expression level of Ulk1 vs Ulk2. (A) Gene expression of 
Ulk1 vs Ulk2 in E14.5 embryos showing greater expression of Ulk2 in the 
CNS (Genepaint). (B) In situ hybridization of Ulk1 and Ulk2 mRNA in 8 week 
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Chapter 2. Aβ42 oligomers trigger synaptic loss through coordinated AMPK-dependent 
activation of mitochondrial fission and mitophagy  
 
2.1 Introduction to the Chapter 
 Our lab previously published a paper examining the role of the CAMKK2-AMPK 
pathway in Aβ42o induced synaptotoxicity. The paper highlights that the hyperactivation of 
CAMKK2-AMPK drives the synapse loss in excitatory PNs both in vitro and in vivo in J20 AD 
mice. It also illustrates that tau functions downstream of AMPK, supporting the current 
hypothesis that tau lies downstream of Aβ42o (Mairet-Coello et al., 2013). Another study from 
the Klann laboratory nicely supported the significant role of AMPK using electrophysiology, 
underlining that Aβ42o induced LTP disruption can be prevented upon inhibition of AMPK 
activation or genetic ablation of AMPKα2 (Ma et al., 2014). We decided to further examine the 
role of AMPK in the progression of AD, especially in the context of mitochondrial disruption. 
This is in part because AMPK serves as a regulator in multiple aspects of mitochondrial 
remodeling and homeostasis in part through its downstream effectors including MFF and Ulk 
proteins (Herzig & Shaw, 2018). Moreover, we wanted to understand the relationship between 
some of the mitochondrial defects reported in ND and synaptotoxicity. Therefore, we 
hypothesized that hyperactivation of AMPK can disrupt the mitochondrial network as well as 
synapse loss. The manuscript for the project is fully complete and is currently under review at 
Neuron. Based on our equal contribution, a postdoctoral fellow in our lab, Dr. Chandana 
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2.2.1 Summary  
 
During the early stages of Alzheimer’s disease (AD) in both mouse models and human 
patients, soluble forms of Amyloid β1-42 oligomers (Aβ42o) trigger the loss of excitatory 
synapses (synaptotoxicity) in cortical and hippocampal pyramidal neurons (PNs) prior to the 
formation of insoluble Aβ plaques. We observed a spatially restricted structural remodeling of 
mitochondria in the apical tufts CA1 PNs dendrites in the hAPPSWE,IND transgenic AD mouse 
model (J20), corresponding to the dendritic domain where the earliest synaptic loss is detected in 
vivo. Recent work uncovered that Aβ42o mediates its synaptotoxic effects in vitro and in vivo by 
over-activating the CAMKK2-AMPK kinase dyad, and that AMPK is a central regulator of 
mitochondria homeostasis in non-neuronal cells. Here, we demonstrate that Aβ42o-dependent 
over-activation of AMPK mediates synaptic loss through coordinated MFF-dependent 
mitochondrial fission and ULK2-dependent mitophagy in dendrites of PNs. Our results uncover 
a causal link between Aβ42o-dependent structural remodeling of mitochondria and synaptic loss 
in neurons. 
 
2.2.2 Introduction  
 
Alzheimer’s disease (AD) is the most prevalent form of dementia in humans leading to socially 
devastating cognitive defects with no effective treatment. AD is characterized by two hallmark 
lesions including amyloid plaques composed of fibrillar forms of amyloid-beta (Aβ) and 
neurofibrillary tangles (NFT) composed of aggregated, hyperphosphorylated tau. Before the 
formation of amyloid plaques and NFT, amyloidogenic processing of amyloid precursor protein 
(APP) by β- and γ-secretase produces abnormal accumulation of a 42-amino acid-long amyloid 
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beta (Aβ42) peptide. Aβ42 peptides have a strong ability to oligomerize and form dimers, 
trimers, and higher order oligomers that ultimately fibrillate to form Aβ plaques (Sheng et al., 
2012). Oligomeric forms of Aβ42 (Aβ42o) lead to early loss of excitatory synapses 
(synaptotoxic effects) in cortical and hippocampal pyramidal neurons (PNs) before plaque 
formation, strongly suggesting that synaptotoxicity is an early event in the disease progression 
triggered by soluble Aβ42o (Hong, Beja-Glasser, et al., 2016; Mairet-Coello et al., 2013; 
Masliah et al., 2001; Moolman et al., 2004; Shankar et al., 2007). This phenotype has been 
observed in various AD mouse models including the J20 transgenic mouse model (APPSWE, IND) 
where progressive loss of excitatory synaptic connections occur before Aβ plaque formation 
(Jacobsen et al., 2006; Mairet-Coello et al., 2013; Mucke, Maslia, et al., 2000). Soluble Aβ42o 
extracted biochemically from AD patients or produced synthetically also lead to rapid synaptic 
loss in PNs in vitro (Jin et al., 2011; Lacor et al., 2004; Lacor et al., 2007; Mairet-Coello et al., 
2013; Shankar et al., 2007; Shankar et al., 2008). 
A second phenotype observed in the early stages of AD progression is structural abnormalities of 
mitochondria. Because of the terminally postmitotic status and extreme degree of 
compartmentalization of neurons of the central nervous system (CNS), maintaining 
mitochondrial homeostasis in neurons is highly dependent on the dynamic balance of 
fission/fusion and efficient autophagic degradation of aged and damaged mitochondria (Ashrafi 
& Schwarz, 2015; Schwarz, 2013). Mitochondrial fission is carried out by a GTPase protein 
called Drp1 that needs to be recruited to the outer mitochondrial membrane (OMM) by various 
proteins including MFF, Fis1, MiD49, and MiD51. The fusion machinery includes Mfn1/2 that is 
involved in fusion of OMM and OPA1 involved in inner mitochondrial membrane fusion (Burte 
et al., 2015; D. C. Chan, 2006; Youle & van der Bliek, 2012). PNs show strikingly 
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compartmentalized morphology of their mitochondria in the somatodendritic versus axonal 
domains. In most cells, mitochondria play critical physiological functions that might differ 
between dendrites and axons such as ATP production, Ca2+ buffering, and/or lipid biosynthesis 
(T. L. Lewis, Jr. et al., 2013). Recent evidence points to significant structural remodeling of 
dendritic mitochondria in hippocampal neurons in multiple AD mouse models and AD patients 
(Burte et al., 2015; Du et al., 2010; Itoh, Nakamura, Iijima, & Sesaki, 2013; Wang, Su, Lee, et 
al., 2009; Xie et al., 2013; Zhang et al., 2016), which is one of the earliest affected brain regions 
in AD in mouse models and AD patients (Arriagada, Marzloff, & Hyman, 1992; Busche et al., 
2012; Serrano-Pozo et al., 2011). However, the role played by changes in mitochondria structure 
and/or function in the disease progression in vivo, especially in relation to synaptotoxicity, 
remains untested. Moreover, the molecular mechanisms that could link changes in mitochondria 
structure and synaptic loss remain unknown.  
Results from our lab as well as others demonstrated that in neurons, Aβ42o over-activates AMP-
activated kinase (AMPK) in a calcium/calmodulin kinase kinase protein 2 (CAMKK2) 
dependent manner and preventing CAMKK2 or AMPK over-activation either pharmacologically 
or genetically protects hippocampal neurons from Aβ42o-dependent synaptic loss in vitro and in 
the hAPPSWE, IND transgenic mouse model (J20) in vivo (Ma et al., 2014; Mairet-Coello et al., 
2013; Son et al., 2012; Thornton et al., 2011). Importantly, AMPK is over-activated in the brain 
of AD patients where catalytically active AMPK accumulates in pyramidal neurons of the cortex 
and hippocampus (Vingtdeux et al., 2011). In non-neuronal cells, AMPK is a key metabolic 
sensor which, when ATP levels drop in cells, is catalytically activated by increasing levels of 
AMP/ADP and regulates various downstream effectors involved in maintaining mitochondrial 
integrity in part via two recently identified downstream effectors: mitochondrial fission factor 
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(MFF) and Unc-51 like autophagy activating kinases 1/2 (ULK1/2) (Egan et al., 2011; Toyama 
et al., 2016). MFF is an outer mitochondrial protein with two identified AMPK phosphorylation 
sites. Upon AMPK activation, MFF enhances the recruitment of the fission protein Drp1, which 
is important for efficient fragmentation of mitochondria (Toyama et al., 2016), a step thought to 
be required for efficient mitophagy. The second and coordinated step regulated by AMPK 
activation are the ULK proteins. ULK1 (also called Atg1) has multiple AMPK phosphorylation 
sites and functions in an evolutionarily conserved process called autophagy. Autophagy is 
involved in degrading cytoplasmic components via lysosomes, often under nutrient stress to 
obtain energy. Importantly, autophagy is the only known mechanism for degrading organelles 
including mitochondria (mitophagy). Mounting evidence has also implicated altered autophagy 
in the pathogenesis of AD as abnormal autophagic vacuole (AV) build-up in neurites of AD 
patients at least at late stages of the disease progression (Nixon, 2013). Therefore, we wanted to 
test if the CAMKK2-AMPK pathway could be the first pathway identified to coherently regulate 
the major AD phenotypes and more precisely if Aβ42o-dependent over-activation of AMPK 
triggers synaptic loss through its ability to mediate mitochondrial structural remodeling. 
In the present study, we discovered that hippocampal CA1 PNs display remarkably 
compartmentalized structural remodeling of dendritic mitochondria in the J20 AD mouse model 
in vivo: we observe significant loss of mitochondrial biomass only in the apical tuft dendrites of 
CA1 PNs which, most significantly, corresponds to the dendritic compartment in the 
hippocampus where loss of dendritic spines can be first observed in this AD mouse model. We 
demonstrate that Aβ42o application induces coincidental mitochondria fission and loss of 
mitochondrial biomass through mitophagy in dendrites of cortical PNs via coordinated 
phosphorylation and activation of two critical AMPK effectors: MFF and ULK2. Importantly, 
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individual manipulation of either MFF or ULK2 prevents Aβ42o-dependent dendritic spine loss, 
demonstrating a causal link between Aβ42o-dependent mitochondria structural remodeling and 
synaptic maintenance. Our results (1) demonstrate that the novel CAMKK2-AMPK-MFF-ULK2 
pathway mediates Aβ42o-dependent synaptic loss through its ability to induce structural 
remodeling of dendritic mitochondria, (2) provide the first ‘unifying’ signaling pathway 
explaining many of the cellular defects reported in AD mouse models and in the brain of AD 
patients during early stages of the disease progression, such as Aβ42o-dependent Tau 
phosphorylation (Mairet-Coello et al., 2013), increased autophagy, defective mitochondrial 
integrity, defect in Ca2+ homeostasis (Sheng et al., 2012) and (3) provide a causal link between 
reduction of dendritic mitochondrial biomass and synaptic loss. 
 
2.2.3. Results  
2.2.3A. Spatially restricted structural remodeling of mitochondria and synaptic loss 
in apical tufts dendrites of CA1 hippocampal PNs in the APPSWE, IND mouse model 
The J20 mouse line is a powerful model to study the effect of amyloidosis in AD pathogenesis as 
it expresses the human Amyloid-Precusor-Protein (APP) carrying two mutations found in 
familial forms of AD (APPSWE, IND) and show Aβ42o accumulation in the hippocampus (Mucke, 
Maslia, et al., 2000). For this study, we chose to focus on the analysis of mitochondrial 
morphology and dendritic spine density in CA1 hippocampal neurons, which are among the first 
and the most affected in AD patients and AD mouse models (Perez-Cruz et al., 2011; Pozueta et 
al., 2013; Serrano-Pozo et al., 2011). Using sparse in utero hippocampal or cortical 
electroporation (E15àP21), we were able to visualize dendritic mitochondria morphology and 
spine density in optically isolated dendritic segments of hippocampal CA1 PNs or layer 2/3 
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pyramidal neurons (Fig. S1). Interestingly, in WT mice, layer 2/3 cortical PNs display elongated 
and fused dendritic mitochondria, forming a complex network throughout the entire dendritic 
arbor (Fig. S1B, D, F, H). In sharp contrast, CA1 PNs display a high degree of 
compartmentalization of mitochondrial morphology in dendrites of WT mice: in basal and apical 
oblique dendrites, mitochondria are mostly small and punctate whereas the distal apical dendrites 
contain elongated and fused mitochondria ((Fig. 1A, C, E and Fig. S1G). The transition between 
these two types of mitochondrial morphology is sharp and corresponds to the boundary between 
the hippocampal layer stratum radiatum (sr; receiving primarily inputs from CA2/CA3 PNs; Fig. 
1B) and stratum lacunosum-moleculare (slm; receiving exclusively presynaptic inputs from the 
medial enthorinal cortex MEC; Fig. 1B). We applied the same experimental approach in both 
WT or J20 littermate mice and examined mitochondrial morphology and spine density in 3-
month-old mice, a time-point where abundant Aβ42o can be detected but preceding appearance 
of amyloid plaques (Mucke, Maslia, et al., 2000). This analysis revealed that, consistent with 
what we observed in WT mice at P21 (Fig. S1), 3-month-old WT and J20 mice both display 
mostly small, punctate mitochondria in basal and apical oblique dendrites (Fig. 1A). This is 
accompanied by a trend but not significant decrease in spine density in basal and apical oblique 
dendrites (Fig. 1A,C). However, the distal apical dendrites of the J20 mice showed a dramatic 
and significant reduction of both mitochondria length and density/biomass as well as a 
significant decreased in spine density compared to WT littermates (Fig. 1A, C, E). These results 
reveal (1) a striking and unique degree of compartmentalization of mitochondrial morphology in 
dendrites of CA1 PNs not observed in cortical layer 2/3 PNs and (2) a spatially restricted loss of 
mitochondrial biomass and spine density specifically in the apical tuft dendrites of CA1 PNs in 
the J20 mouse model. This co-occurrence of mitochondrial remodeling and decreased spine 
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density raised the possibility, tested below, of a potential causal relationship between Aβ42o-









Figure S1. Hippocampal CA1 pyramidal neurons are characterized by highly 
compartmentalized dendritic mitochondria morphology compared to layer 2/3 
cortical pyramidal neurons. Related to Figure 1. 
(A) Low magnification image of hippocampal CA1 pyramidal neurons in utero 
electroporated at E15.5 with pCAG-mTagBFP2 (purple) and pCAG-mito-YFP (green) 
imaged at P21. (B) High magnification image of panel A highlighting that the distal 
apical dendrites in the SLM layer contain high density of mitochondria compared to 
the basal and oblique dendrites (in so and sr, respectively). (C-D) Low magnification 
of a single CA1 pyramidal neuron and a single Layer 2/3 cortical pyramidal neuron. 
(E) High magnification of CA1 PN shown in C highlighting that mitochondria in the 
basal and oblique dendrites are small and fragmented (arrowheads). (F) High 
magnification of cortical L2/3 PN shown in D, highlighting that mitochondria 
morphology is homogenously elongated (arrow) in basal and proximal apical 
dendrites. (G) High magnification of CA1 PN shown in C highlighting that 
mitochondria morphology in the distal apical tuft dendrites (slm) are elongated unlike 
those found in basal and oblique dendrites of the same cell (see E). (H) High 
magnification of cortical L2/3 PN highlighting that mitochondria morphology is 
homogenously elongated in distal apical dendrites similar to those found in both basal 
and oblique dendrites in the same neuron (see F). Abbreviations: slm, stratum 
lacunosum moleculare; sr, stratum radiatum; so, stratum oriens; sp, stratum 
pyramidalis 
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Figure 1. In AD mouse model, CA1 pyramidal neurons display spatially restricted 
mitochondrial fragmentation and loss of biomass in distal apical tufts 
(A) Representative images of CA1 PN dendrites from different regions of WT control and J20 
mice. CA1 PNs were electroporated with pCAG-Venus and pCAG-mito-DsRed by in utero 
electroporation in E15.5 WT and J20 mouse embryos. Both mouse groups were fixed and 
imaged at 3 months postnatal (P90). Dendrites from basal, oblique, and distal apical are 
magnified to show spine density and mitochondrial morphology. The three types of dendrites 
were characterized as displayed in (B) for both WT and J20 mice. (C-E) Quantification of spine 
density (C) and individual mitochondrial length (D)  and mitochondrial density (fraction of 
dendritic segment length occupied by mitochondria) (E). Data is represented by box plots 
displaying minimum to maximum values, with the box denoting 25th, 50th (median) and 75th 
percentile from at least 3 independent in utero electroporated mice. Nbasal WT  = 47 dendrites, 595 
mitochondria; Nbasal APP  = 32 dendrites, 495 mitochondria; Noblique WT  = 46 dendrites, 630 
mitochondria; Noblique APP  = 33 dendrites, 507 mitochondria; Ndistal WT = 39 dendrites, 284 
mitochondria; Ndistal APP = 32 dendrites; 426 mitochondria . All the analysis was done blind to 
the experimental conditions, and was manually counted using FIJI. Statistical analysis was 
performed using Kruskal-Wallis test followed by Dunn’s post-hoc test in (C-E). The test was 
considered significant when p<0.05 with the following criteria: * p<0.05; ** p<0.01; 
***p<0.001; ****p<0.0001; ns, p>0.05. Scale bar= 2µm.  
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2.2.3B. Aβ42o induces synaptic loss and dendritic mitochondrial remodeling in the same 
time frame 
To examine the temporal relationship between mitochondrial remodeling and 
synaptotoxicity, we wanted to adopt an in vitro model that would allow us to control the timing 
of Aβ42o application. We turned to long-term cortical PNs cultures (Mairet-Coello et al., 2013), 
which are synaptically connected and display uniformly fused mitochondria throughout their 
dendritic arbor in vitro (Fig. 2) as in vivo (Fig. 1 and S1). We observed significant, time-
dependent changes in dendritic mitochondrial structure following acute Aβ42o application 
including both a reduction of their length (fragmentation) and in mitochondrial density (Fig. 
2A’-C’; Fig. 2D-E). In the same neurons, we observed a progressive reduction in dendritic spine 
density in Aβ42o treated neurons between 14 and 24hr following Aβ42o application (Fig. 2A-C, 
Fig. 2F). No significant changes in mitochondria morphology were observed in the soma or the 
axon of the same neurons (data not shown) or, as previously reported, when control inverted 
peptide (INV42) were applied at similar concentrations than Aβ42o (Fig. S2) (Lacor et al., 2004; 
Lacor et al., 2007; Mairet-Coello et al., 2013; Shankar et al., 2007). Our lab has previously 
published that at this dose and duration, Aβ42o application does not affect neuronal viability, 
strongly suggesting that the effects we observe are not a secondary consequence of 
compromising neuronal survival (Mairet-Coello et al., 2013). Taken together, our results 
highlight that Aβ42o application triggers a significant degree of time-dependent, structural 
remodeling of dendritic mitochondria including reduction of mitochondrial biomass concomitant 
with a reduction in spine density, which is a reliable index of excitatory synapse number in 
dendrites of PNs (Harnett, Makara, Spruston, Kath, & Magee, 2012).  
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Figure 2. Aβ42o induces dendritic mitochondrial fragmentation and dendritic spine loss within 
the same time frame. 
(A-C’) Representative images of primary cortical neurons at 21 days in vitro (DIVs). Neurons 
express Venus (A,B,C) and mito-DsRed (A’, B’, C’) to assess spine density and mitochondrial 
morphology, respectively. At 20 DIVs, neurons were treated with either 24 hours of control vehicle, 
14 or 24 hours of Aβ42 oligomers (1µM monomer equivalent). High magnification of secondary 
dendrites is shown below whole neurons shown at low magnification. (D) Quantification of 
dendritic mitochondrial length. (E) Quantification of dendritic mitochondria density. Dendritic 
mitochondria density was calculated by summing up the length of all the mitochondria then dividing 
it by the length of the dendrite examined. (F) Quantification of dendritic spine density calculated by 
dividing the number of spines by the length of the dendrite examined. All the analysis was done 
blind to the experimental conditions, and was done by manual counting using FIJI. All of the 
statistical analyses were performed with Prism 6 (GraphPad Software). Data is represented by box 
plots displaying minimum to maximum values, with the box denoting 25th, 50th (median) and 75th 
percentile from 3 independent experiments. ncontrol = 53 dendrites, 278 mitochondria; n14hr Aβ42  = 47 
dendrites; 380 mitochondria; n24hr Aβ42= 51 dendrites; 400 mitochondria. Statistical analysis was 
performed using Kruskal-Wallis test followed by Dunn’s post-hoc test in (D-F). The test was 
considered significant when p<0.05 with the following criteria: * p<0.05; ** p<0.01; ***p<0.001; 
****p<0.0001; ns, not significant. Scale bar for high magnification dendritic segments= 2µm.  
	 57  
Figure S2. Treatment of inverse oligomeric Aβ42 does not influence mitochondrial morphology 
or spine density. Related to Figure 2. (A) Representative high magnification images of dendritic 
segments showing dendritic spines in the upper panel and mitochondria in the lower panel. Treatment 
of inverse Aβ42 oligomers (1uM monomer equivalent) does not affect spine density or mitochondrial 
morphology and have similar parameters as DMSO treated neurons (B) Mitochondrial length for 
inverse Aβ42 is comparable to DMSO treated neurons while Aβ42 oligomer treatment significantly 
reduces mitochondrial length. (C) Mitochondrial density for inverse Aβ42 is comparable to DMSO 
treated neurons while Aβ42 oligomer treatment significantly reduces mitochondrial density. (D) Spine 
density quantification for inverse Aβ42 is comparable to DMSO treated neurons while Aβ42 oligomer 
treatment significantly reduces spine density. All the analysis was done blind to the experimental 
conditions, and was done by manual counting using FIJI. Data is represented by box plots displaying 
minimum to maximum values, with the box denoting 25th, 50th (median) and 75th percentile from 3 
independent experiments. nINV  = 41 dendrites,  243 mitochondria; nveh = 31 dendrites; 178 
mitochondria; n Aβ42o = 33 dendrites, 245 mitochondria. Statistical analysis was performed using 
Kruskal-Wallis test followed by Dunn’s post-hoc test in (B-D). The test was considered significant 
when p<0.05 with the following criteria: * p<0.05; ** p<0.01; ***p<0.001; ****p<0.0001; ns, not 
significant. Scale bar= 2µm. (E) 16.5% Tris-Tricine SDS-PAGE was performed to resolve Aβ42 
oligomers that were generated as described in Methods. Immuno-blotting was performed with 6E10 
antibody which shows a mixture of monomers, dimers and trimers in lane 1 and 2 (two independent 
oligomerization experiments). For quantifying effective oligomer concentration in lane 1 and 2, Near-
infrared fluorescence signal intensity was measured for dimer+trimer and monomer using Odyssey 
Imager. Signal intensity values for Lane1: Dimer+Trimer-1510; monomer-1830. Signal intensity 
values for Lane2: Dimer+Trimer-736; monomer-1720. 
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2.2.3C Aβ42o application induces local mitophagy in dendrites 
We next tested whether changes in mitochondrial biomass observed upon Aβ42o treatment is 
triggered in dendrites of PNs by local mitophagy. To that end, we examined the dynamics of 
autophagosomes, lysosomes, autolysosomes as well as changes in mitochondrial biomass in 
cortical PNs upon Aβ42o treatment using sparse ex utero electroporation of plasmids encoding 
mito-mTagBFP2, LAMP1-mEmerald, and RFP-LC3 to visualize mitochondria, lysosomes, and 
autophagosomes, respectively. Cortical PNs were cultured for at least 21DIV in high-density 
cultures, where they display mature synapses (Mairet-Coello et al., 2013), and imaged live using 
time-lapse confocal microscopy every 15 minutes for 14 hours following treatment with either 
control (vehicle) or Aβ42o (Fig. 3). In control treated neurons, we observed little to no change in 
mitochondrial biomass or in the dynamics of LC3+ (autophagosomes), LAMP1+ (lysosomes) or 
LC3+/LAMP1+ (autolysosomes) vesicles (Fig. 3A-A’’). On the contrary, upon Aβ42o treatment, 
we observed a significant accumulation of both LC3+ and LAMP1+ puncta in dendrites over 
time as visualized in Fig. 3A (see kymograph in Fig. 3A”). In dendrites exposed to Aβ42o, many 
of the LC3+ puncta became co-localized with LAMP1+, suggesting these autolysosomes often 
occur locally. LC3+/LAMP1+ autolysosomes do form occasionally in control dendrites (Fig. 
3A’’-B). As shown in Fig. 3B, treatment with Aβ42o leads to an almost 5-fold increase in the 
percentage of dendritic segments with increased LC3+/LAMP1+ autolysosomes accumulation 
compared to control treatment. Both LC3 and LAMP1 normalized fluorescence intensity showed 
time-dependent increases upon Aβ42o application, highlighting local biogenesis of autophagic 
vacuoles and their coalescence with lysosomes in dendritic shafts upon Aβ42o treatment, 
respectively (Fig. 2C-E). We also observed a significant reduction in mitochondria fluorescence 
(as measured via mt-mTAGBFP2, (Fig. 2E)) in a spatially restricted area close to 
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LC3+/LAMP1+ puncta as indicated by the yellow arrow in the representative image (Fig. 3A) 
and the kymograph (Fig. 3A”). Not all LC3+/LAMP1+ puncta correlated with loss of a 
mitochondria within 14h of time-lapse imaging as indicated by the red arrow in the 
representative image (Fig. 3A-A”). To quantify spatial dynamics of mitophagy, we defined a 
‘mitophagy index’ along segments of dendrites by measuring the intensity of mt-mTagBFP2 
fluorescence using line scan intensity measurements in regions of interest (ROI) without or with 
LC3+/LAMP1+ puncta. This index reflects loss of mitochondrial biomass in or out of areas 
where autophagosomes and lysosomes coalesce to generate autolysosomes.  In control 
conditions, the formation of LC3+/LAMP1+ puncta is not only a rare event (Fig. 3A-B), but the 
presence of LC3+/LAMP1+ puncta do not seem to result in loss of mitochondria biomass by 
mitophagy (Fig. 3F). On the other hand, when measuring mitochondria along the dendrite upon 
Aβ42o treatment, we observed very spatially restricted mitophagy events, only found in ROIs of 
the dendrites that display LC3+/LAMP1+ autolysosomes demonstrating that significant levels of 
mitophagy occur locally in dendrites of cortical PNs upon Aβ42o treatment. 
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Figure. 3. Aβ42o treatment induces local mitophagy in dendrites 
(A) Dendritic segments (secondary) from primary cortical PNs at 21-25 DIVs 
electroporated with plasmids encoding mito-mTagBFP2, Lamp1-mEmerald, and RFP-
LC3 to visualize mitochondria, lysosomes, and autophagosomes, respectively, using ex 
utero electroporation on embryos at E15.5. At 21DIVs, neurons were treated with control 
vehicle or Aβ42o and imaged live with time-lapse microscopy every 15 minutes for 14 
hours. The captured image shows dendrites at 0 and 14 hours for both conditions. Yellow 
box labels the zoomed region shown in (A’) illustrating that in control, there is no 
significant change of LAMP1+ (lysosomes) and LC3+ (autophagosomes) or LC3/LAMP1 
double-positive (autolysosomes) vesicles dynamics or accumulation and no significant 
change in mitochondrial morphology (see also Movie S1 and S2). In contrast, in dendrites 
of Aβ42o treated cortical PNs, sites of LAMP1-LC3 double-positive autolysosome 
accumulation often results in loss of mitochondria as indicated by yellow arrow in A’. We 
note that some sites do not display loss of mitochondrial signal as within the 14h of 
imaging following Aβ42o application (red arrow in Fig. 2A). (A’’) Representative 
kymograph of mitochondria, lysosomes, and autophagosomes in dendrites from Fig. 2A. 
(B) Percentage of dendritic segments showing accumulation of both LC3+ 
autophagosomes, LAMP1+ lysosomes or LC3/ LAMP1-double positive autotlysosomes. 
Data is represented by box plots displaying minimum to maximum values, with the box 
denoting 25th, 50th (median) and 75th percentile from 3 independent experiments. ncontrol = 
15 neurons; nAβ42 = 24 neurons (C) Quantification of LAMP1  fluorescence intensities in 
dendritic segments for both conditions were normalized to LAMP1 intensity at to. All 
dendritic segments that displayed significant accumulation of LAMP1 and LC3 in Aβ42o 
treated condition in Fig. 2B were included in the analysis. All the dendrites that showed 
accumulated LAMP1 and LC3 in control condition were included in the analysis, as well 
as randomly selected dendrites that did not show accumulation to match the number of 
dendrites analyzed in Aβ42 condition. Over time, Aβ42 treated dendrites show significant 
increase in LAMP1 intensity. (D) Quantification of LC3 intensities in dendritic segments 
for both conditions were normalized to LC3 intensity at time point zero. Only, but all, the 
dendrites that showed accumulated LAMP1 and LC3 in Aβ42 treated condition in Fig. 8D 
were included in the analysis. All the dendrites that showed accumulated LAMP1 and 
LC3 in control condition were included in the analysis, as well as randomly selected 
dendrites that did not show accumulation to match the number of dendrites analyzed in 
Aβ42 condition. Overtime, Aβ42 treated dendrites show significant increase in LC3 
intensity. (E) Quantification of mitochondrial intensities in dendritic segments for both 
conditions were normalized to mitochondrial intensity at time point zero. Only, but all, the 
dendrites that showed accumulated LAMP1 and LC3 in Aβ42 treated condition in Fig. 2B 
were included in the analysis. All the dendrites that showed accumulated LAMP1 and 
LC3 in control condition were included in the analysis, as well as randomly selected 
dendrites that did not show accumulation to match the number of dendrites analyzed in 
Aβ42 condition. Overtime, Aβ42 treated dendrites show significant decrease in 
mitochondrial intensity. Data for Fig. 2C-E is represented as normalized intensity over 
time for each respective marker from 3 independent experiments. ncontrol = 222 dendrites; 

















(F) Random dendritic segments analyzed in Fig 2B were selected to measure level of 
mitophagy. To obtain a spatially specific measurement of mitophagy, intensity line scan 
measurements were taken across different dendritic regions from the same dendrite. For each 
dendrite, line scans were drawn in regions without and with LC3 and LAMP1 puncta at 14 
hours and the intensity of mitochondrial signal was measured at time point zero and 14 hours. 
Fold change of mitochondrial intensity at a very spatially focused area was calculated. In 
control, mitochondrial index across the same dendrite is relatively unchanged in regions with 
and without LC3 and LAMP1 accumulation, suggesting that mitochondria are not targeted for 
LC3/LAMP1 degradation. In Aβ42 treated condition, mitochondrial index along the same 
dendrite can show significant difference. Only regions of LC3 and LAMP1 accumulation 
show mitochondrial loss. Data is represented as bar graph from n control conditions = 33 dendrites; 
n Aβ42 conditions = 44 dendrites. One-way ANOVA with Kruskal-Wallis followed by Dunn’s 
post-hoc test were applied. The test was considered significant when p<0.05 with the 
following criteria: * p<0.05; ** p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Scale 
bar= 2µm. 
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2.2.3D. Aβ42-dependent mitochondrial fragmentation and synaptotoxicity are mediated by 
CAMKK2-AMPK over-activation 
We have previously shown that Aβ42o-dependent over-activation of the CAMKK2-AMPK 
kinase dyad mediates dendritic spine loss both in primary cortical PNs culture and in 
hippocampal PNs in the J20 AD mouse model, (Mairet-Coello et al., 2013). Since AMPK is a 
central regulator of mitochondrial homeostasis (Garcia & Shaw, 2017; Herzig & Shaw, 2018), 
we wanted to test if the CAMKK2-AMPK pathway was required for Aβ42o-induced dendritic 
mitochondrial remodeling in pyramidal neurons in vitro using a conditional double floxed mouse 
line (AMPKα1F/F/α2F/F). AMPKα1F/F/α2F/F embryos were electroporated with (1) a control 
plasmid lacking Cre recombinase or a plasmid expressing Cre recombinase along (2) with Venus 
fluorescent protein to visualize spine morphology and (3) mt-dsRed to examine mitochondrial 
morphology. Quantitative analysis indicated that in basal conditions AMPKα1/α2 null neurons 
have spine and mitochondrial densities indistinguishable from wildtype neurons. Strikingly, 
AMPKα1/α2 null neurons are completely protected from Aβ42o-induced mitochondrial density 
reduction (Fig. 4A) as well as synaptotoxicity as previously reported (Mairet-Coello et al., 
2013). This demonstrates that over-activation of AMPK is required for both Aβ42o-induced 
mitochondria structural remodeling and spine loss in dendrites of PNs. 
AMPK has two upstream regulatory kinases namely, LKB1 and CAMKK2 which 
phosphorylates AMPKa subunit on T172 and significantly increases its catalytic activity (Garcia 
& Shaw, 2017). However, in neurons, CAMKK2 has been identified as the primary upstream 
regulator of AMPK (Hardie, Ross, & Hawley, 2012; Mairet-Coello et al., 2013; Son et al., 2012). 
Therefore, we assessed if pharmacologically blocking CAMKK2 acutely interfered with Aβ42o 
effects on mitochondrial structural remodeling and dendritic spine loss. Pretreatment of primary 
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neuronal cultures with STO-609, a specific CAMKK2 inhibitor (Tokumitsu et al., 2002), 
completely blocked Aβ42o-induced mitochondrial structural remodeling (Fig. S3A-C) as well as 


























Figure 4.  Oligomeric Aβ42 induced synaptotoxicity and dendritic mitochondrial 
fragmentation is AMPK dependent  
(A) Dendritic segments (secondary) of primary cortical neuron at 21 DIV. Embryos from 
AMPKα1/2 double conditional knockout (AMPKα1F/F/2F/F) were ex utero electroporated at 
E15.5 with plasmids expressing Venus, mito-DsRed, and either scrambled Cre (control) or 
Cre recombinase. Neurons were treated at 20 DIV with either control or Aβ42o at 1µM 
monomer equivalent for 24 hr. (B-D) Quantification of mitochondria length (B), and 
mitochondrial density (C), and spine density (D) in individual dendritic segments. All the 
analysis was done blind to the experimental conditions, and was done by manual counting 
using FIJI. All of the statistical analyses were performed with Prism 6 (GraphPad Software). 
Data is represented by box plots displaying minimum to maximum values, with the box 
denoting 25th, 50th (median) and 75th percentile from 3 independent experiments. n-Cre control = 
27 dendrites, 128 mitochondria; n-Cre Aβ42o  = 29 dendrites; 204 mitochondria; n+Cre control = 29 
dendrites; 143 mitochondria; n+Cre Aβ42o =24 dendrites, 112 mitochondria. Statistical analysis 
was performed using Kruskal-Wallis test followed by Dunn’s post-hoc test in (B-D). The 
test was considered significant when p<0.05 with the following criteria: * p<0.05; ** 







Figure S3. Oligomeric Aβ42 induced synaptotoxicity and dendritic mitochondrial 
fragmentation is CAMKK2 dependent. Related to Figure 4. 
(A) Dendritic segments (secondary) of primary cortical neuron at 21 DIV. Embryos at 
E15.5 were ex utero electroporated with pCAG-Venus and pCAG-mito-DsRed. At 20 
DIV, neurons were pre-treated with either DMSO or STO609 (2.5mM) for 2 hours before 
being treated with either control or Aβ42 oligomers at 1µM monomer equivalent for 24 
hr. Blocking CAMKK2 activity by STO609 blocks both dendritic mitochondrial 
remodeling and synaptotoxicity. (B) Quantification of dendritic mitochondrial length, (C) 
dendritic mitochondrial density, and (D) spine Density. All the analysis was done blind to 
the experimental conditions, and was done by manual counting using FIJI. Data is 
represented by box plots displaying minimum to maximum values, with the box denoting 
25th, 50th (median) and 75th percentile from 3 independent experiments. nDMSO Control  = 37 
dendrites, 163 mitochondria; nDMSO Aβ42o = 31 dendrites; 248 mitochondria; nSTO609 control = 
37 dendrites; 163 mitochondria; nSTO609 Aβ42o = 35 dendrites,  157 mitochondria. All of the 
statistical analyses were performed with Prism 6 (GraphPad Software). Statistical 
analysis was performed using Kruskal-Wallis test followed by Dunn’s post-hoc test in (B-
D). The test was considered significant when p<0.05 with the following criteria: * 
p<0.05; ** p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Scale bar= 2µm.  
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2.2.3E. Aβ42o-induced MFF over-activation causally links mitochondrial fragmentation 
and synaptic loss. 
In non-neuronal cells, AMPK has been identified as a major metabolic sensor regulating ATP 
homeostasis upon induction metabolic stress through its ability to phosphorylate many 
downstream effectors involved in various aspects of metabolism regulation (Hardie et al., 2012; 
Herzig & Shaw, 2018). As part of this metabolic stress response, AMPK regulates mitochondrial 
fission through direct phosphorylation of mitochondrial fission factor (MFF) which enhances its 
ability to recruit Drp1 to the outer mitochondria and therefore promotes mitochondrial fission 
(Toyama et al., 2016). To that end, we tested if MFF is the effector mediating AMPK-dependent 
Aβ42o-induced mitochondrial fission and if blocking MFF-dependent fission can prevent spine 
loss. Upon exposure of Aβ42o, cortical PNs that express MFF shRNA (knockdown efficacy 
shown in Lewis et al., 2018) are protected from loss of mitochondrial biomass in dendrites (Fig. 
5A-C) and from spine loss (Fig. 5A, D). Interestingly, knockdown of MFF in basal condition 
does not affect either the dendritic mitochondrial length and density or the spine, strongly 
suggesting that the signaling pathway we have identified is a bona fide stress response pathway 
in dendrites upon Aβ42o exposure, as we have previously hypothesized (Mairet-Coello & 
Polleux, 2014). Altogether, these results suggest a causal relationship between Aβ42o-induced 











Figure 5. MFF is required for Aβ42o induced dendritic mitochondrial fragmentation  
(A) Representative images of secondary dendritic segments of primary cortical neurons at 21 
DIV. Embryos at E15.5 were ex utero electroporated with plasmids encoding Venus, mito-
DsRed, and either with control shRNA or an shRNA specific for mouse MFF (MFF shRNA). 
Neurons were treated at 20 DIV with either control or Aβ42o at 1µM monomer equivalent for 
24 hours. Knockdown of MFF blocks both the synapse and dendritic mitochondrial 
fragmentation. (B) Quantification of dendritic mitochondrial length, and (C) dendritic 
mitochondrial density, and (D) spine density. All the analysis was done blind to the 
experimental conditions, and was done by manual counting using FIJI. All of the statistical 
analyses were performed with Prism 6 (GraphPad Software). Data is represented by box plots 
displaying minimum to maximum values, with the box denoting 25th, 50th (median) and 75th 
percentile from 3 independent experiments. nPLKO control = 36 dendrites, 188 mitochondria; nPLKO 
Aβ42o  = 41 dendrites; 300 mitochondria; nMFFshRNA control = 36 dendrites; 167 mitochondria; 
nMFFshRNA Aβ42o = 30 dendrites, 125 mitochondria. Statistical analysis was performed using 
Kruskal-Wallis test followed by Dunn’s post-hoc test in (B-D). The test was considered 
significant when p<0.05 with the following criteria: * p<0.05; ** p<0.01; ***p<0.001; 
****p<0.0001; ns, not significant. Scale bar for magnified dendritic segments= 2µm. 
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2.2.3F. Aβ42o-induced MFF phosphorylation by AMPK is required for dendritic 
mitochondrial fragmentation and synaptic loss.  
To determine if MFF is phosphorylated by Aβ42o-dependent AMPK over-activation in neurons, 
we measured AMPK-mediated phosphorylation on MFF at Serine 146 (S146) and total MFF in 
primary cortical neurons (Fig. S4). As a positive control to show that the MFF S146 site is 
regulated by AMPK activation, we over-expressed the human isoform of MFF in Neuro2A 
(N2A) neuroblastoma cells and treated with or without Metformin, a potent activator of AMPK 
(Toyama et al., 2016) (Fig. S4). Firstly, Aβ42o application for 24h on long-term cortical PNs 
cultures showed a significant increase in AMPK phosphorylation at T172 site as previously 
reported (Mairet-Coello et al., 2013; Thornton et al., 2011) (Fig. S4). As a consequence of 
AMPK activation, we observe an increase in phosphorylation of MFF at S146 in cortical neurons 
which is comparable to Metformin treatment of N2A cells (Fig. S4). This experiment 
demonstrates that Aβ42o leads to AMPK dependent phosphorylation and activation of MFF in 
cortical PNs.   
In order to test if AMPK-dependent phosphorylation of MFF is required for Aβ42o-dependent 
mitochondrial remodeling, we took a gene replacement approach where we identified a low 
levels of MFF WT and MFF AA expression that, in combination with MFF shRNA, does not 
lead to mitochondrial fragmentation in control condition. Cortical PNs expressing titrated levels 
of MFF WT showed both mitochondrial and spine loss following 24hr of Aβ42o treatment (Fig. 
6C-F) to levels comparable to control neurons whereas neurons expressing titrated levels of 
MFF AA were protected from Aβ42o-induced mitochondrial structural remodeling and spine 
loss (Fig. 6C-F). These results demonstrate a causal role of Aβ42o-triggered mitochondrial 






Figure S4. Aβ42 dependent increase in MFF phosphorylation. Related to 
Figure 6.  
Cortical PNs maintained in dissociated neuronal culture were treated at 20DIV 
with either control or Aβ42o at 1µM monomer equivalent for 24 hours. N2A cells 
were treated with either DMSO or 2mM of Metformin for 5 hours as positive 
control for AMPK- dependent MFF phosphorylation (Toyama et al., 2016). 80µg 
of whole cell lysate was immunoprecipated with MFF antibody (Progen) and 
immunoblotted with MFF antibody or phospho-MFF antibody (S146, CST). 
Whole cell lysates were also immunoblotted with phospho-AMPK (T172, CST) 
and AMPK to confirm activation of AMPK under both Aβ42 oligomers at 1µM 
monomer equivalent for 24 hours (Mairet-Coello et al., 2013) and metformin 
treatment (Toyama et al., 2016).  
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Figure 6. Aβ42o induces AMPK-dependent MFF phosphorylation at two serine sites 
required for Aβ42o-dependent dendritic mitochondrial fragmentation and spine loss  
(A) Representative images of secondary dendritic segments of primary cortical neurons at 
21 DIVs. Embryos at E15.5 were ex utero electroporated with pCAG-Venus and pCAG-
mito-DsRed to visualize spines and mitochondria, respectively. Neurons were also 
electroporated with MFFshRNA along with either low levels of pCAG-MFF-WT or 
pCAG-MFF-AA mutant constructs and treated with either control or Aβ42 oligomers at 
1µM monomer equivalent for 24 hours. Gene replacement (MFFshRNA + MFF AA) with 
a form of MFF that cannot be phosphorylated by AMPK blocks dendritic mitochondrial 
fragmentation and spine loss. (B) Quantification of dendritic mitochondrial length, and 
(C) dendritic mitochondrial density, and (D) spine density. All the analysis were done 
blind to the experimental conditions, and performed by manual counting using FIJI. Data 
is represented by box plots displaying minimum to maximum values, with the box 
denoting 25th, 50th (median) and 75th percentiles from 3 independent experiments. 
nMFFshRNA + MFFWT Control  = 31 dendrites, 166 mitochondria; nMFFshRNA + MFFWT Aβ42o = 29 
dendrites; 228 mitochondria; nMFFshRNA + MFFAA control = 35 dendrites; 164 mitochondria; 
nMFFshRNA + MFFAA Aβ42o =28 dendrites, 137 mitochondria. Statistical analysis was performed 
using Kruskal-Wallis test followed by Dunn’s post-hoc test in (D-F). The test was 
considered significant when p<0.05 with the following criteria: * p<0.05; ** p<0.01; 
***p<0.001; ****p<0.0001; ns, not significant. Scale bar in A: 2µm. 
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2.2.3G. Activation of ULK2 by AMPK leads to loss of mitochondrial biomass following 
MFF-dependent mitochondrial fission  
In non-neuronal cells under conditions of metabolic stress, AMPK activation not only triggers 
increased mitochondrial fission through phosphorylation and activation but also trigger 
mitophagy by directly phosphorylating the autophagy initiating kinase, ULK1 (Atg1). Since we 
observed (1) increased mitophagy in dendrites exposed to Aβ42o and (2) a significant decrease 
in mitochondrial biomass following increased AMPK-MFF-dependent fission between 14-24h of 
Aβ42o treatment (Fig. 1 and 5), we hypothesized that over-activation of AMPK by Aβ42o also 
activates the observed increased levels of mitophagy by activating ULK1 and/or ULK2, two 
isoforms of ULK implicated in mitophagy and highly expressed in cortical neurons (Egan et al., 
2011; Kim et al., 2011).  
We tested first if either one or both of the two isoforms of the ULK1/2 mediate Aβ42o-induced 
synaptotoxicity by performing shRNA-mediated knockdown of either ULK1 or ULK2 (Fig. 
S5A). Interestingly, we found that knockdown ULK2, but not ULK1, protected cortical PNs 
from Aβ42o-induced spine loss at 24h (Fig. S5C). We then tested if loss of ULK2 could protect 
Aβ42o-treated neurons from loss of mitochondrial biomass. We sparsely expressed Cre-
recombinase in primary cortical PNs isolated from a conditional ULK2 mouse line (ULK2F/F) 
(Cheong, Lindsten, Wu, Lu, & Thompson, 2011)  along with Venus as a cell filler and mt-dsRed 
to visualize mitochondria. Loss of ULK2 completely blocks Aβ42o-induced loss of 
mitochondrial biomass, but the mitochondria are still fragmented compared to the controls (Fig. 
7A-C), compatible with the AMPK-MFF dependent induction of mitochondrial fission being 
intact in these ULK2-deficient neurons. This further supports the current idea that mitochondrial 
fission and mitophagy are coupled events such that mitochondrial fragmentation must occur to 
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enable mitophagy (D. C. Chan, 2006; Schwarz, 2013). Interestingly, preservation of 
mitochondrial density/biomass upon ULK2 conditional deletion was sufficient to rescue Aβ42o-
induced synaptotoxicity (Fig.7A and D). Therefore, our data suggest that these two parallel 
effectors (MFF and ULK2) coincidentally activated by AMPK act in a concerted manner to 
couple fission and mitophagy in neuronal dendrites and most importantly that loss of 


















Figure S5. ULK2 but not ULK1 lies downstream is required for Aβ42o-dependent 
synaptotoxic effects. Related to Figure 7. 
(A) Representative images of secondary dendritic segments of primary cortical neurons 
treated with either control or Aβ42 oligomers (1µM monomer equivalent) at 21DIV for 24 
hours. Embryos were subjected to ex-utero electroporation at E15.5 with pCAG-Venus and 
control shRNA or an shRNA specific for the kinase ULK1 or ULK2. Knockdown of ULK2, 
but not ULK1 kinase blocks oligomeric Aβ42o-induced synaptotoxicity. (B) Western blot 
showing validation of ULK1 and ULK2 shRNA and the specificity of the shRNAs for the 
respective isoform. HEK 293T cells were transiently co-transfected with control shRNA or 
ULK1/ULK2 shRNA along with over-expressed myc-mULK1 and Flag-mULK2 
respectively and western blotting was performed with 25µg of lysate with the indicated 
antibody. (C) Quantification of spine density for Fig. S4A. All the analysis was done blind to 
the experimental conditions, and was done by manual counting using FIJI. All of the 
statistical analyses were performed with Prism 6 (GraphPad Software). Data is represented 
by box plots displaying minimum to maximum values, with the box denoting 25th, 50th 
(median) and 75th percentile from 3 independent experiments. nPLKO control = 31 dendrites; 
nPLKO Aβ42o = 27 dendrites; nULK1shRNA control = 27 dendrites; nULK1shRNA Aβ42o = 24 dendrites; 
nULK2shRNA control = 33 dendrites; nULK2shRNA Aβ42o = 35 dendrites. Statistical analysis was 
performed using Kruskal-Wallis test followed by Dunn’s post-hoc test in (C). The test was 
considered significant when p<0.05 with the following criteria: * p<0.05; ** p<0.01; 
***p<0.001; ****p<0.0001; ns, not significant. Scale bar= 2µm. 
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Figure 7. ULK2 acts in a concerted manner with MFF and leads to loss of mitochondrial 
biomass following MFF-dependent mitochondrial fragmentation. 
(A) Representative images of secondary dendritic segments of primary cortical neurons at 
21DIV. ULK2F/F embryos were ex utero electroporated at E15.5 with plasmids encoding with 
Venus and mitoDsRed as well as either scrambled Cre (control; -Cre) or Cre recombinase 
(+Cre). Neurons were treated at 21 DIV with either control or Aβ42o (1µM monomer 
equivalent) for 24 hours. Deletion of ULK2 in cortical PNs blocks Aβ42o-induced loss of 
dendritic spines and loss of mitochondrial biomass. (B-D) Quantification of dendritic 
mitochondrial length (B), dendritic mitochondrial density (C), and dendritic spine density (D). 
Analysis was done blind to the experimental conditions by manual counting using FIJI. 
Statistical analysis was performed using one-way ANOVA with Kruskal-Wallis followed by 
Dunn’s post-hoc test in (B-D). Data is represented by box plots displaying minimum to 
maximum values, with the box denoting 25th, 50th (median) and 75th percentile from 3 
independent experiments. N-CRE DMSOcontrol = 36 dendrites, 193 mitochondria; n-CRE Aβ42o = 38 
dendrites; 254 mitochondria; n+CRE DMSOcontrol  = 36 dendrites; 186 mitochondria; n+CRE Aβ42o = 
35 dendrites,   435 mitochondria. The test was considered significant when p<0.05 with the 
following criteria: * p<0.05; ** p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Scale 
bar for magnified dendritic segments= 2µm. 
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2.2.3H. AMPK phosphorylation of ULK2 is required for Aβ42o-induced dendritic 
mitophagy and synaptic loss  
We next tested if AMPK-mediated phosphorylation of ULK2 is required for Aβ42o-dependent 
synaptotoxic effects in cortical PNs. Extensive studies in non-neuronal cells have established that 
the closest ortholog of ULK2, ULK1, is phosphorylated and thereby catalytically activated by 
AMPK and plays a key role in regulating mitophagy (Egan et al., 2011; Kim et al., 2011). 
Although the two orthologs seem to have redundant functions in non-neuronal cells, the above 
results uncovered that, in cortical PNs that only downregulation of ULK2, but not ULK1, 
completely blocks Aβ42-mediated synaptotoxicity (Fig. S5C). Therefore, we performed a 
sequence homology analysis of candidate AMPK sites identified in ULK1 and compared them to 
ULK2. Two independent groups collectively reported six AMPK-mediated phosphorylation sites 
on ULK1 (Egan et al., 2011; Kim et al., 2011). Using primary sequence alignment between 
human and mouse ULK1/2, we have found that four of these ULK1 phosphorylation sites are 
conserved in ULK2 and are predicted as bona fide AMPK consensus phosphorylation sites 
(Fig.8A and Fig.S6C; S309/T441/S528/S547). To verify that these sites are the four most 
prevalent AMPK target sites in ULK2, we mutated these four candidate S/T residues to alanine 
in ULK2 (ULK2-4SA) and over-expressed them in HEK293T cells. We then performed 
immunoprecipitation (IP) of Flag-tagged ULK2 WT and 4SA mutant from cells that are either 
treated with DMSO or AMPK activator compound 991. Overexpression of constitutively active 
AMPK (CA-AMPK) in the presence of ULK2 WT or ULK2 4SA mutant conditions were used 
as a positive control. Immunoprecipitated Flag-ULK2 WT or Flag-ULK2 4SA were then 
immunoblotted with an antibody recognizing the optimal AMPK phospho-substrate motif. We 
observed basal levels of phosphorylation of ULK2 WT in untreated control which increases upon 
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AMPK activation or when co-expressed with CA-AMPK (Fig. 8B). Importantly, ULK2 
phosphorylation was completely abolished in the 4SA mutant (Fig. 8B), strongly suggesting that 
these four S/T sites are the main AMPK phosphorylation sites in ULK2.  
Finally, we tested if ULK2 phosphorylation by AMPK is required for the loss of mitochondrial 
biomass and the synaptic loss induced Aβ42o application. We performed gene replacement 
experiments taking advantage of ULK2F/F cortical cultures co-electroporated with Cre (or delta 
Cre as negative control) along with ULK2-WT (positive control) or ULK2-4SA or kinase 
inactive ULK2 (ULK2-KI as negative control). We found that expression of ULK2-WT in 
ULK2-null cortical PNs enabled both loss of mitochondrial biomass and synaptic loss induced 
by Aβ42o, but the re-introduction of ULK2 KI or ULK2 4SA had no effect on mitochondrial 
biomass and did not prevent dendritic spine loss (Fig. 8C-F). These results confirm that AMPK 
mediated phosphorylation and activation of ULK2 mediate Aβ42o-dependent synaptic loss 























Figure S6. Schematic of conserved AMPK-mediated 
phosphorylation sites in ULK2. Related to Figure 8. 
Schematic of mULK2 domain structure highlighting the four 
predicted AMPK-mediated phosphorylation sites. (B) ClustalW 
multiple sequence alignment of human and mouse ULK1 and 
ULK2 showing a high degree of conservation of four AMPK-
mediated phosphorylation sites in ULK2 which were previously 
















Figure 8. AMPK mediated phosphorylation of ULK2 is crucial for oligomeric Aβ42 
induced synaptotoxicity and loss of mitochondrial biomass  
A) Schematic of mULK2 domain structure highlighting the four predicted AMPK-mediated 
phosphorylation sites (refer to Fig. S5B) conserved in ULK1 and ULK2. (B) Flag-mULK2 
WT or mULK2 4SA (the four conserved phosphorylation sites shown in Fig.S5B are mutated 
to alanine) is over-expressed in HEK293T cells co-expressing either GST or 
GSTcaAMPKα1(1-312) (constitutively active AMPK). Cells were treated with DMSO or 
50µM compound 991 for 1hour. 5mg of whole cell lysate was immunoprecipitated with anti-
Flag M2 Agarose and immunoblotted with AMPK substrate motif antibody and Flag M2 
monoclonal antibody. 25µg of lysates were immunoblotted for p-Thr172 AMPK, total AMPK 
and actin. (C) Representative high magnification images of dendritic segments showing 
dendritic spines in the upper panel and mitochondria in the lower panel. ULK2F/F embryos 
were ex utero electroporated at E15.5 with control vector (-Cre) or Cre recombinase encoding 
plasmid along with plasmids expressing Venus and mito-DsRed. The Cre-reconstituted (gene 
replacement) conditions were also co-electroporated with either mULK2 WT (Wild-type), 
mULK2 KI (K39I) (Kinase inactive) or mULK2 4SA (See Fig. S5). Neurons were treated at 
20DIV with either control or Aβ42 oligomers at 1µM monomer equivalent for 24 hours. 
Abolishing ULK2 kinase-activity (ULK2 KI) or mutating AMPK-mediated phosphorylation 
sites on ULK2 (ULK2 4SA) can block Aβ42 oligomer induced synaptotoxicity and loss of 
mitochondrial biomass. (D) Quantification of dendritic mitochondrial length, and (E) 
dendritic mitochondrial density, and (F) spine density. Analysis was done blind to the 
experimental conditions by manual counting using FIJI. Statistical analysis was performed 
using one-way ANOVA with Kruskal Wallis followed by Dunn’s post-hoc test in (D-F). Data 
is represented by box plots displaying minimum to maximum values, with the box denoting 
25th, 50th (median) and 75th percentile from 3 independent experiments. NULK2WT DMSOcontrol = 
32 dendrites, 194 mitochondria; nULK2WT Aβ42o = 30 dendrites;  289 mitochondria; nULK2KI 
DMSOcontrol  = 36 dendrites; 183 mitochondria; nULK2KI Aβ42o = 34 dendrites,   449 mitochondria; 
nULK24SA DMSOcontrol  = 34 dendrites; 198 mitochondria; nULK24SA Aβ42o = 32 dendrites,   472 
mitochondria. The test was considered significant when p<0.05 with the following criteria: * 
p<0.05; ** p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Scale bar for magnified 
dendritic segments= 2µm. 
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2.2.4 Discussion  
 
Loss of excitatory glutamatergic synapses in cortical and hippocampal PNs has been reported as 
an early event in AD progression, primarily driven by soluble Aβ42o (Hsieh et al., 2006; Lacor 
et al., 2007; Mucke, Maslia, et al., 2000; Mucke, Masliah, et al., 2000; Shankar et al., 2007; 
Sheng et al., 2012) and this loss of connectivity is thought to be responsible for the early 
cognitive defects characterizing AD patients including defective learning and memory (Sheng et 
al., 2012). Recently, mitochondrial remodeling and dysfunction in PNs have emerged as a 
prominent phenotype in AD (Cho et al., 2009; Wang, Su, Lee, et al., 2009; Wang, Su, Zheng, et 
al., 2009; Zhang et al., 2016). However, whether this structural remodeling of dendritic 
mitochondria is causally linked to excitatory synaptic loss was unknown, in part because the 
molecular mechanism mediating Aβ42o-dependent mitochondrial remodeling were not 
identified. Here we report, using various in vitro and in vivo strategies, that: (1) hyperactivation 
of AMPK by Aβ42o induces mitochondrial remodeling and spine loss in dendrites of cortical 
PNs in vitro and apical tuft dendrites of CA1 PNs in the J20 AD mouse model  in vivo; (2) 
AMPK mediates Aβ42o-dependent mitochondrial fission and mitophagy through coordinated 
activation of MFF and ULK2 respectively; (3) loss of mitochondrial biomass is causally linked 
to synaptic loss induced by Aβ42o.   
AMPK is best-characterized as a metabolic sensor in non-neuronal cells (Herzig & Shaw, 2018). 
Importantly, in AD patients, catalytically active AMPK is abnormally accumulated in the 
cytoplasm of PNs of CA1, entorhinal cortex, and neocortex (Vingtdeux et al., 2011). AMPK 
over-activation has been consistently reported in AD patient brain samples (Ma et al., 2014; 
Vingtdeux et al., 2011), in various AD mouse models (Ma et al., 2014; Mairet-Coello et al., 
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2013; Son et al., 2012), as well as in vitro upon acute treatment of Aβ42o (Ma et al., 2014; 
Mairet-Coello et al., 2013; Thornton et al., 2011; Yoon et al., 2012). 
The CAMKK2-AMPK signaling pathway is unique in its involvement in multiple phenotypes 
observed during the progression of AD. The present study and previous reports collectively 
implicate this signaling pathway as the first to unify multiple phenotypes reported in the brain of 
AD patients and in AD mouse models, including disruption of Ca2+ homeostasis, APP 
processing, tau phosphorylation, mitochondrial remodeling, increased autophagy, and synaptic 
loss (Nixon, 2005, 2013; Sheng et al., 2012). There is growing evidence that one of the earliest 
event upon Aβ42o application is disrupted cytoplasmic Ca2+ homeostasis that drives PNs 
hyperexcitability (see below) (Arbel-Ornath et al., 2017; Busche et al., 2012; Grienberger et al., 
2012; Kuchibhotla et al., 2008; Lerdkrai et al., 2018; Palop & Mucke, 2010). This increased Ca2+ 
accumulation precedes spine morphological changes (Arbel-Ornath et al., 2017), strongly 
suggesting that Ca2+-dependent signaling pathways, including the CAMKK2-AMPK pathway, 
occur early in the disease progression and plays a critical role in reduction of synaptic plasticity 
and synaptic maintenance (Hsieh et al., 2006; Ma et al., 2014; Malinow, 2012). Interestingly, 
Aβ42o-induced AMPK over-activation has been found to induce a vicious cycle of increased 
Aβ42o production via activation of JNK3-dependent APP processing (Yoon et al., 2012). 
Furthermore, AMPK links the two key players of AD: Aβ42o and tau. Catalytically active 
pAMPK has been shown to co-localize with phosphorylated-S262tau in brains of AD patients 
(Vingtdeux et al., 2011), and previous work highlights that hyperactivation of AMPK by Aβ42o 
and /or other AMPK-like kinases such as NUAK1 leads to tau phosphorylation on its KxGS 
motifs – S262 and S356 (Lasagna-Reeves et al., 2016; Mairet-Coello et al., 2013), which is 
thought to act as a priming site for other phosphorylation sites (Waxman & Giasson, 2011). 
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These results demonstrated that the CAMKK2-AMPK signaling pathway links Aβ42o to Tau, 
the two main drivers of synaptic loss (Ittner et al., 2010; Mairet-Coello et al., 2013; Mairet-
Coello & Polleux, 2014; Roberson et al., 2011; Roberson et al., 2007; Thornton et al., 2011).  
In this paper, we identified two new critical effectors of AMPK mediating the effects of Aβ42o 
on synaptic loss. We show that AMPK over-activation by Aβ42o coordinates multiple aspects of 
mitochondrial remodeling by co-regulating mitochondrial fission and mitophagy through its 
activation of MFF and ULK2, respectively. For the first time, we demonstrate that Aβ42o 
mediates loss of excitatory synapses through MFF-ULK2-dependent mitochondrial fission and 
mitophagy. Lastly, what makes this molecular mechanism attractive for development of new 
therapeutical approaches is that it is a true stress-response signaling pathway (Mairet-Coello & 
Polleux, 2014) i.e. these AMPK-dependent pathways are not required for normal neuronal 
development and/or synaptic maintenance in adult cortical and hippocampal neurons (Mairet-
Coello et al., 2013; Mairet-Coello & Polleux, 2014; Williams, Courchet, Viollet, Brenman, & 
Polleux, 2011). Genetic manipulations of AMPK or its downstream effectors do not have any 
identified phenotypic effects on neurons in control conditions, but only upon induction of 
metabolic stress or Aβ42o application in neurons. 
Mitochondrial remodeling and dysfunction are converging mechanisms of disease pathogenesis 
shared by multiple neurodegenerative diseases (ND). This is in part explained by the disruptions 
of mitochondrial homeostasis, motility, and dynamics observed in various ND as well as genetic 
evidence suggesting a strong association between genes involved in mitochondrial function and 
various adult on-set ND syndromes (Itoh et al., 2013; Schon & Przedborski, 2011). In AD 
specifically, altered mitochondrial dynamics have been implicated by the changes of 
mitochondrial fission and fusion protein expression levels in AD patient brains (Wang, Su, Lee, 
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et al., 2009) and various AD mouse models (Wang et al., 2008), as well as altered 
posttranslational modification of Drp1 thought to disrupt mitochondrial dynamics (Cho et al., 
2009; Wang, Su, Lee, et al., 2009). In line with our results, Wang, et al., (2009) also observe that 
in the presence of Aβ42o, dendritic mitochondria decrease in length and density, which is 
correlated with reduced spine density. Interestingly, a recent study suggested a significant degree 
of mitochondrial structural remodeling in various AD mouse models and AD patients in the CA1 
of the hippocampal region using 3D EM reconstructions (Zhang et al., 2016). Our present study 
further corroborates these observations and provides a molecular mechanism mediating Aβ42o-
dependent mitochondrial remodeling and synaptic loss during early stages of AD.  
A second cellular defect thought to contribute to several neurodegenerative diseases including 
AD is a disruption of autophagy-lysosomal pathway (Nixon, 2013). Although the cellular and 
molecular mechanisms of autophagy have been examined using non-neuronal cells (Mizushima, 
2007), recent results demonstrated unique, compartment-specific regulation of autophagy in 
neurons. Local biogenesis of autophagosomes has been observed in distal axons and traffic 
retrogradely towards the soma in order to fuse with lysosomes, whereas autophagosomes in the 
soma are more stationary (Maday & Holzbaur, 2016). However, the dynamics of autophagy in 
dendrites remains largely unexplored. However, much of what we know on neuronal autophagy 
has been primarily focused on axonal and presynaptic autophagy dynamics, where it mediates 
efficient synaptic transmission by regulating the turnover of synaptic proteins (Uytterhoeven et 
al., 2015). Interestingly, autophagosome (AP) formation occurs in distal axons and can traffic 
retrogradely to fuse with lysosomes that are localized closer to the soma (Maday & Holzbaur, 
2016). Autophagy has received significant attention in AD research, in part due to the abnormal 
accumulation of AP and autolysosomes (AL) in dystrophic neurites of AD patients (Nixon, 
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2005). Moreover, familial mutations and polymorphisms associated with AD link to dysfunction 
of the autophagic-lysosomal pathway. Mutations of the Presenillin (PS) 1 and 2 proteins have 
been shown to disrupt lysosomal acidification and autophagy (J. H. Lee et al., 2015). AD 
associated genes such as PICALM, BIN1, RAB11, and VPS34 are involved in various initiation, 
sorting, and trafficking processes of autophagy (Ando et al., 2016; Miyagawa et al., 2016; Morel 
et al., 2013; Udayar et al., 2013). However, much of the cellular phenotypes of AP and AL 
buildup have been described at late stages of AD when neurodegeneration involving actual 
neuronal cell loss occurs (Nixon, 2005) . More recent results suggested that, in AD mouse 
models, autophagic flux is disrupted (Son et al., 2012) and expression level of mitophagy genes 
are elevated during the early stages of AD (Sorrentino et al., 2017). Our results demonstrate that 
Aβ42o triggers an AMPK-ULK2 dependent increase in mitophagy resulting in a significant local 
degradation of dendritic mitochondria and most interestingly, that this cell biological step is 
causally linked with synaptic loss since we rescue dendritic spine loss induced by Aβ42o in 
cortical PNs where ULK2 phosphorylation by AMPK is disabled.  
Our in vivo analysis also reveals a striking and previously unknown degree of 
compartmentalization of mitochondria morphology in dendrites of CA1 PNs: in basal and apical 
oblique dendrites, mitochondria are small and punctate whereas the distal apical dendrites 
contain elongated and fused mitochondria (Fig. S1). The transition between these two types of 
mitochondrial morphology is sharp and actually corresponds to the transition between stratum 
radiatum (sr) and stratum lacunosum moleculare (slm).  
 
As discussed above, disruption of Ca2+ homeostasis has been observed in various AD mouse 
models (Busche et al., 2012; Grienberger et al., 2012; Lerdkrai et al., 2018), in wildtype PNs 
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exposed to acute treatment of oligomeric Aβ42 in vivo (Arbel-Ornath et al., 2017), and neuronal 
culture exposed to Aβ42o in vitro (Demuro et al., 2005; Guo et al., 1999). Recent results 
suggested that disruption of Ca2+ dynamics is largely due to Aβ42o, as immune-depletion of 
Aβ42o can prevent this phenotype (Arbel-Ornath et al., 2017) and increase the population of 
hyperactive neurons (Busche et al., 2012; Grienberger et al., 2012). Possible explanations of this 
increased cytoplasmic Ca2+ accumulation include increased mobilization of Ca2+ from 
extracellular space through NMDAR and VGCC, increased leakage of Ca2+ from intracellular 
Ca2+ storing organelles such as the ER, and loss of Ca2+ buffering capacity by the neurons. 
Currently, there is evidence supporting that Ca2+ is derived from the extracellular influx of Ca2+ 
via NMDAR (Arbel-Ornath et al., 2017; Sheng et al., 2012) as well as the Ca2+ released from the 
ER via the IP3R and RyR (S. L. Chan, Mayne, Holden, Geiger, & Mattson, 2000; Stutzmann, 
Caccamo, LaFerla, & Parker, 2004). Regardless of the Ca2+ source, PNs ultimately experience 
intracellular Ca2+ increase that can activate Ca2+-dependent signaling pathway, including our 
CAMKK2-AMPK pathway. There may be a complex positive feed-forward loop where Aβ42o-
dependent, fast NMDAR-dependent Ca2+ influx (Arbel-Ornath et al., 2017) over-activates the 
CAMKK2-AMPK pathway resulting in reduction of mitochondrial biomass, i.e. mitochondrial 
matrix volume, and therefore reduced Ca2+ buffering capacity, further increasing cytoplasmic 
Ca2+ accumulation. It is tempting to speculate that the significant degree of Aβ42o-dependent 
reduction in dendritic mitochondrial biomass and the ensuing reduction in spine density in these 
distal dendritic segments  identified in the present study in the apical tuft dendrites of CA1 PNs 
in the J20 AD mouse model could contribute to degradation of the spatial tuning properties of 
these neurons at early stages of the disease progression. Future investigations will need to 
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2.2.6 Material and method  
Animals 
Mice were used according to protocols approved by the Institutional Animal Care and Use 
Committee (IACUC) at Columbia University and in accordance with National Institutes of 
Health guidelines. Time-pregnant CD1 females were purchased from Charles Rivers. 129/SvJ, 
C57Bl/6J nontransgenic mice and hemizygous transgenic mice from line J20 (hereafter referred 
as J20) (The Jackson Laboratory stock #006293) were maintained in a 12-hour light/dark cycle. 
J20 mice express human APP carrying the Swedish and Indiana mutations under a PDGFβ 
promoter (Mucke, Maslia, et al., 2000; Palop et al., 2007). AMPKα1F/Fα2F/F double conditional 
knockout mice were a generous gift from Dr. Benoit Viollet (INSERM, Institut Cochin, Paris). 
Ulk2F/F mice were obtained from The Jackson Laboratory stock #017977 (Cheong et al., 2011). 
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Timed-pregnant females were obtained by overnight breeding with males of the same strain. 
Noon the day after the breeding was considered as E0.5.  
 
Synthetic Aβ42 oligomers preparation  
Aβ42 (rPeptide or Creative Peptide) was processed to generate Aβ42 oligomers as described 
previously (Mairet-Coello et al., 2013). Briefly, lyophilized Aβ42 peptide was dissolved in 
hexafluoro-2-propanol (HFIP; Sigma-Aldrich) for 2 hours to allow monomerization. HFIP was 
removed by speed vacuum, and the monomers were stored in -80°C. Aβ42 monomers were 
dssolved in anhydrous dimethyl sulfoxide (DMSO) to make a 5mM solution, then added to cold 
phenol red-free F12 medium (Life Technology) to make a 100uM solution. The solution was 
incubated at 4°C for two days and centrifuged at 12,000 x g for 10 min at 4°C in order to discard 
the fibrils. The supernatant containing the 4°C oligomers were assayed for protein content using 
the BCA kit (Thermo Fisher Scientific). For control experiments, vehicle treatment corresponded 
to the same volume of DMSO and F12 media used for Aβ42o treatment and for Figure S2, a 
peptide corresponding to the inverted sequence of Aβ42 (INV42; rPeptide and Creative Peptide) 
was processed as for Aβ42 oligomerization. For western blotting of Aβ42 oligomers, 16.5% 
Tris-Tricine SDS-PAGE was performed. Synthetic Aβ42 oligomers were prepared in 2X Tricine 
sample buffer (BIORAD) without reducing agent and resolved by SDS-PAGE. The separated 
proteins were transferred onto Immobilin-FL PVDF membrane (EMD Millipore), blocked for 1 
hour with Odyssey blocking buffer (LICOR) and probed with 6E10 monoclonal antibody 
(Covance) overnight at 4°C. Secondary antibody incubation was performed for 1 hour at room 
temperature with IRDye 680RD goat anti-mouse secondary (LICOR) and the blot was visualized 
and quantified using the Odyssey Imaging system.  
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Primary cortical culture and ex utero electroporation 
Cortices from E15.5 mouse embryos were dissected followed by dissociation in complete Hank’s 
balanced salt solution (cHBSS) containing papain (Worthington) and DNase I (100ug/mL, 
Sigma) for 15 minutes at 37°C, washed three times, and manually triturated in DNase I 
(100ug/mL) containing neurobasal medium (Life Technology) supplemented with B27 (1x, 
Thermo Fischer Scientific,), FBS (2.5%, Gibson) N2 (1x, Thermo Fischer Scientific), glutaMAX 
(2mM, Gibco). Cells were plated at 10.0 X 104 cells per 35 mm glass bottom dish (Mattek) that 
has been coated with poly-D-lysine (1mg/mL, Sigma) over night. One-third of the medium was 
changed every 5 days thereafter with non-FBS containing medium and maintained for 20-25 
days at 37°C in 5% CO2. Ex utero electroporation was performed as previously published 
(Courchet et al., 2013). See the Supplemental Experimental Procedures for details and 
constructs.  
 
In utero hippocampal electroporation 
In utero electroporation targeting the hippocampus was performed as previously described (Hand 
& Polleux, 2011; Mairet-Coello et al., 2013) with slight modifications as described in 
(Szczurkowska et al., 2016) to target the embryonic hippocampus at E15.5. See Supplemental 
Experimental Procedures for more details.  
 
Imaging 
Imaging on dissociated neurons was performed between 20-25 DIV in 1,024 x 1,024 resolution 
with a Nikon Ti-E microscope equipped with A1R laser-scanning confocal microscope using the 
Nikon software NIS-Elements (Nikon, Melville, NY, USA). We used the following objective 
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lenses (Nikon): 10x PlanApo; NA 0.45 (for images of hippocampal slices), 60X Apo TIRF; NA 
1.49 (for analysis of spine densities and mitochondrial morphology in cultured neurons), 100x H-
TIRF; and NA 1.49 (for analysis of spine densities and mitochondrial morphology in brain 
slices). Dendritic spine density was quantified on secondary or tertiary dendritic branches that 
were proximal to the cell body, on z projections for cultured neurons and in the depth of the z 
stack for slices, using FiJi software (ImageJ; NIH). See Supplemental Experimental Procedures 
for more details.   
 
Cell Lysis and Immunoprecipitation 
Neurons cultures were washed with cold PBS and lysed in Triton Lysis Buffer: 20mM HEPES 
(pH 7.5), 150mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.25M Sucrose, 
Complete™protease inhibitor (Roche), and phosphoSTOP (Roche). Lysates were incubated at 
4°C for 15 minutes and cleared at 15,000 x g for 15 minutes at 4°C. Total protein was 
normalized using Bio-rad Protein Assay Dye (Bio-rad).  
For western blotting of phospho-T172 AMPK and total AMPK, equal amounts of lysates were 
loaded on a Mini-Protean TGX (4-20%) SDS-PAGE (Bio-rad). The separated proteins were 
transferred onto polyvinylidene difluoride membrane (PVDF, Bio-Rad), blocked for 1 hour with 
blocking buffer containing 5% fat-free dry milk in TBS-T. Membranes were then incubated 
overnight at 4°C with different primary antibodies diluted in the same blocking buffer. 
Incubations with HRP conjugated secondary antibodies were performed for 1 hour at room 
temperature, and visualization was performed by chemiluminescence.   
For phospho-MFF and MFF, equal amounts of lysates (80mg) were immunoprecipitated with 
MFF or HA (as negative control for specific binding) to enhance MFF proteins. SureBeadsTM 
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Protein A Magnetic Beads were washed three times with lysis buffer and added to equilibrated 
lysates for 1 hour at 4°C. The beads were washed 2 times with lysis buffer, two times with lysis 
buffer without Triton X-100, and then eluted by boiling in SDS lysis buffer for 5 minutes at 
95°C and resolved by SDS-PAGE (Bio-rad) gel. The separated proteins were transferred onto 
polyvinylidene difluoride membrane (PVDF, Bio-Rad), blocked for 1 hour with blocking buffer 
containing 5% BSA in Tris-buffered saline solution. Membranes were incubated overnight at 
4°C with either phospho or total MFF primary antibodies diluted in the same blocking buffer. 
Clean-BlotTM IP Detection Kit (Thermo Fisher Scientific) was used to detect the bands of interest 
without the detection of denatured IgG as MFF protein size is close to both heavy and light 
chain. After overnight primary antibody incubation, membranes were incubated with Dilute 
Clean-Blot IP Detection Reagent at 1:100 for 1 hour at room temperature and visualization was 
performed by enhanced chemiluminescence. 
For phospho-ULK2 experiments, 293T cells were transfected using Lipofectamine 2000 (Life 
Technologies) according to manufacturer's instructions with pcDNA3 plasmids encoding flag 
tagged WT ULK2, flag tagged K39I ULK2 (ULK2 KI) or flag tagged 
S309A,T441A,S528A,S547A ULK2 (SA4). Where indicated, cells were co-transfected with a 
constitutively active truncated version of AMPKa1 (caAMPK). 
Transfected cell lysates were harvested 40-48 hours post transfection. 1 hour after changing the 
media with fresh media containing vehicle or 50µM compound 991 (Glixx laboratories, Inc.), 
cells were washed with cold PBS and lysed in lysis buffer: 20 mM Tris pH 7.5, 150 mM NaCl, 1 
mM EDTA, 1mM EGTA, 1% Triton X-100, 2.5 mM pyrophosphate, 50 mM NaF, 5 mM β-
glycero-phosphate, 50 nM calyculin A, 1 mM Na3VO4, and protease inhibitors (Roche). Lysates 
were incubated at 4°C for 15 minutes and cleared at 16,000g for 15 minutes at 4°C. Total protein 
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was normalized using BCA protein kit (Pierce) and lysates were resolved on SDS-PAGE gel. 
Immunoprecipitations were performed by adding magnetic M2 FLAG beads (Sigma) to 
equilibrated lysates for 2 hours at 4°C. The beads were washed three times with lysis buffer and 
then eluted by boiling in SDS lysis buffer for 5 minutes and resolved by SDS-PAGE.  
Antibodies used in the paper are the following: anti-phospho-T172-AMPKα (40H9, 1:1000, Cell 
Signaling); AMPKα1/2 (1:1000, Cell Signaling); MFF (1:1000, Proteintech); phospho-S146-
MFF (1:1000, Cell Signaling); pAMPK motif (CST, #5759S); total AMPKa (CST, #2532), Flag 
M2 (Sigma, F7425), pACC (CST, #3661), pRaptor (CST, #2083), pAMPK (CST, #2535), 6E10 
anti-β amyloid antibody (Covance), actin (Sigma, A5441). HRP-coupled secondary antibodies to 
mouse (AP124P) or rabbit (AP132P) were from Millipore. 
 
Statistics 
Statistical analyses were performed with Prism 6 (GraphPad Software). The statistical test 
applied for data analysis is indicated in the corresponding figure legend. Experimental groups 
where all distributions were Gaussian/normal were assessed using the unpaired t-test for two-
population comparison, or one-way ANOVA with Dunnett’s post hoc test for multiple 
comparisons. Nonparametric tests including the Mann-Whitney U test for two-population 
comparison and kruskal-Wallis with Dunn’s posttest for multiple comparisons were applied 
when distributions were not Gaussian. Unless otherwise noted, data are expressed as mean ± 
SEM. For dendritic spine and mitochondrial morphology analysis, all data were obtained from at 
least three independent experiments or at least three individual mice. The test was considered 
significant when p<0.05. For all analyses, the following apply: * p<0.05; ** p<0.01; *** 
p<0.001; **** p<0.0001; ns, not significant with p > 0.05.  
	 93 
Constructs 
pSCV2-Venus and pCAG-mito-dsRed were described in previous publication (T. L. Lewis, Jr., 
Turi, Kwon, Losonczy, & Polleux, 2016). pLKO-MFFsh specific for mouse was obtained from 
Sigma Aldrich (TRCN0000174665). Validation of the shRNA knockdown efficiency was done 
elsewhere (Lewis et al., 2018). cDNA encoding Renalin, MFF WT (Uniprot Q9GZY8 isoform 
5), and MFF AA were described previously (Toyama et al., 2016) and sublconed in the pCAG 
plasmid backbone  3’ to CAG promoter using PCR. 0.25mg/mL of individual constructs were 
used for the MFF rescue experiments. pCAG-Cre and pCAG-Scrambled Cre were described in 
previous publications (Courchet et al., 2013). pcDNA3-flag-ULK2 specific for mouse was 
obtained from Addgene (#27637) and was used to generate the kinase-inactive (K39I) and 
serine-to-alanine 4SA mutant (S309/T441/S528/S547A) using Quikchange II site directed 
mutagenesis kit (Agilent technologies) and were subcloned into pCAG vector backbone using 
PCR. pSUPER-scrambled, ULK1 shRNA and ULK2 shRNA constructs were validated in a 
previous study (Zhou et al., 2007).  
 
In utero hippocampal electroporation 
Timed pregnant hybrid F1 females were obtained by mating inbred 129/SvJ females and 
C57Bl/6J males. These F1 females were then mated with J20 males to obtain both mice that do 
express the APP transgene and mice that do not express the transgene in the same littermate. In 
utero electroporations were performed as detailed in (Szczurkowska et al., 2016) with the 
exception that J20 mice were used. Briefly, a mix of endotoxin-free plasmid preparation 
(PSCV2-mVenus -1mg/mL, pCAG-mitoDsRed -0.5mg/mL) was injected into both lateral 
hemisphere of E15.5 embryos using a picospritzer. Electroporation was performed with triple 
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electrode to target hippocampal progenitors in E15.5 embryos by placing the two anodes 
(positively charged) on either side of the head and the cathode on top of the head at a 0° angle to 
the horizontal plane. Four pulses of 45V for 50ms with 500ms interval were used for the 
electroporation.  
 
Tissue slice preparation and Immunofluorescence 
Animals were sacrificed 3 months after birth by terminal transcardial perfusion of 4% 
paraformaldehyde (PFA, Electron Microscopy Sciences) followed by overnight post-fixation in 
4% PFA. Brains were washed 3X with PBS for 5 minutes and sectioned at 100µm thickness 
using vibratome (Leica). Sections were permeabilized with 0.2% Triton X-100 3X for 5 minutes, 
blocked in PBS based blocking buffer with 5% BSA and 0.2% Triton, and stained with chicken 
anti-GFP (Aves, 1:1000) and rabbit anti-RFP (Abcam, 1:1000) for enhancement of PSCV2-
mVenus and pCAG-mitoDsRed, respectively overnight at 4°C. Sections were washed with 0.2% 
Triton buffer 3X for 5 minutes and incubated with Alexa488- and Alexa 555- labeled secondary 
antibodies for PSCV2-mVenus and pCAG-mitoDsRed, respectively overnight at 4°C. Sections 
were washed with 0.2% Triton buffer 3X for 10 minutes each and mounted using VectaShield® 
Mounting Medium (Vector Laboratory). 
 
Drug Treatments  
Neuronal cells at 20-25 DIV were treated with STO609 (2.5µM, Millipore), a CAMKK2 
inhibitor, 2.5 hours prior to Aβ42 treatment. N2A cells were transfected with pCAG-MFF-WT 
construct using the recommended protocol from FuGENE®HD Transfection Reagent overnight. 
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Cells were treated with either DMSO or Metformin (2mM, Sigma) for 5 hours before cells were 
lysed using Triton lysis buffer as described under Cell Lysis and Immunoprecipitation.   
 
Analysis of Spine Density and Mitochondrial Morphology 
Dendritic spine densities were estimated on secondary or tertiary dendritic branches for cultured 
neurons and in the depth of the z stack for slices, using FiJi software (ImageJ, NIH). The length 
of the dendritic segment was measured on the z projection, which implies the density could be 
overestimated. To limit this issue, only dendrites that were parallel to the plane of the slices were 
analyzed. Spines were quantified over an average of 40µm in cultures (between 2-3 segments per 
cell) and 40µm in vivo (between 2-3 segments per cell). Spine density was defined as the number 
of quantified spines divided by the length over which the spines were quantified. The criteria for 
measuring mitochondrial length for each dendritic segment were same as above. Mitochondrial 
density was defined as the total sum of all the mitochondria divided by the length over which the 
mitochondria lengths were measured.  
 
Analysis of Mitophagy Events 
For Fig.3B, manual counting of total number of dendrites and number of dendrites showing 
accumulation of fluorescently-tagged LC3 and LAMP1 was performed for all imaged neurons. 
To confirm both LC3 and LAMP1 accumulation over time following Aβ42o application using an 
independent quantification approach, we selectively examined all of the 251 dendritic segments 
categorized as showing LC3+/LAMP1+ accumulation upon Aβ42o application and measured the 
intensities of LC3 and LAMP1 fluorescence (within an ROI ranging from 20-30µm in length) 
over time. All the dendrites that showed accumulation of LC3 and LAMP1 in control conditions 
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were also analyzed, as well as randomly selected dendritic segments that did not show detectable 
accumulation of LC3 and LAMP1. Optical density of LAMP1-mEmerald and LC3-RFP 
fluorescence were normalized to the initial starting fluorescence intensities at t0 (DF/F0). For 
these selected dendrites, mito-mtagBFP2 intensities were also measured over time for Fig. 3E. 
To measure local mitophagy events as indicated in Fig. 3F, random dendrites analyzed in Fig.3B 
were selected for each condition. For a given dendritic segment, intensity line scan analysis 
(pixel neighborhood-1 pixel) was performed where two vertical lines were drawn: one along the 
region of dendrite without LC3/LAMP1 puncta and one along the region with LC3/LAMP1 
puncta. The fold change of mitochondrial intensity from time point zero to 14hr after respective 
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2.3 Additional preliminary results  
The following preliminary results are not in the manuscript currently but are of relevance to the 
project.  
2.3.1. Oligomeric Aβ42o induced mitochondrial remodeling and spine loss is rescued 
upon NAC exposure in vitro.  
 To determine whether buildup of ROS could contribute to the mitochondrial remodeling 
induced by acute Aβ42o, I hypothesized that introduction of the anti-oxydant N-acetyl-cysteine 
(NAC) before and throughout Aβ42o treatment might have a protective effect on synaptic loss in 
PNs. I cultured primary cortical PNs from E15.5 embryos that have been ex utero electroporated 
with pCAG-Venus and pCAG-mito-DsRed to examine neuronal and mitochondrial morphology, 
respectively. These cultures were aged for at least 20 DIVs when they reach mature spine 
density. At 20 DIVs, cultures were treated with either 1µM monomeric equivalent of Aβ42o, 
which our lab has calculated to average around 400nM of oligomeric species of Aβ42o (Lee and 
Kondapalli et al., submitted), or pretreated with 5mM of NAC for 2 hours before additional 
treatment with 1µM of Aβ42o. After 24 hours of treatment of either Aβ42o or pre-treatment with 
NAC before the 24 hours Aβ42o exposure, neurons were imaged to study mitochondrial 
morphology. As expected, 24-hour treatment of oligomeric Aβ42o led to both mitochondrial 
fission and degradation. Interestingly, pre-treatment with 5mM NAC led to the protection of 
mitochondrial remodeling suggesting that build up of ROS, in part induces Aβ42o-mediated 











Additional Figure 1. Oligomeric Aβ42o induced mitochondrial remodeling and spine 
loss is rescued upon NAC exposure in vitro. (A) Representative images of primary cortical 
neurons at 21 DIV ex utero electroporated with pCAG-mito-DsRed at E15.5. Neurons were 
treated either with vehicle (24hr), Aβ42 oligomers (1µM monomer equivalent for 24 hr, 
calculated to be around 400nM of Aβ42 oligomers), or pretreated with 5mM N-acetylcysteine 
(NAC) for 2 hours followed by Aβ42 oligomer treatment. (B) Quantification of dendritic 
mitochondrial length and (C) dendritic mitochondria density. Data is represented by box plots 
displaying minimum to maximum values with the box denoting 25th, 50th and 75th percentile 
from one experiment. Nveh  = 12 dendrites, 88 mitochondria; NAβ42o = 9 dendrites, 108 
mitochondria; NAβ42o + NAC = 12 dendrites, 115 mitochondria. Statistical analysis was 
performed using Kruskal-Wallis test followed by Dunn’s post-hoc test in (B-C). The test was 
considered significant when p<0.05 with the following criteria: * p<0.05; ** p<0.01; 
***p<0.001; ****p<0.0001; ns, not significant.  
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2.3.2. Overexpression of MFF WT and AA can alter mitochondrial morphology and spine 
density. 
 The data in the manuscript uses “gene replacement” technique to examine the role of 
wildtype and phospho-mutant MFF that contains mutations on the two AMPK phosphorylation 
sites from serine to alanine on S172 and S155 (MFF AA) upon exposure to Aβ42o. In vitro, our 
results show that MFF WT and AA constructs have an overexpression effect and induce strong 
dendritic mitochondria fragmentation (Additional figure 2A). Briefly, E15.5 embryos were ex 
utero electroporated with pCAG-mito-DsRed, pCAG-Venus, and either with Control, MFF WT, 
or MFF AA construct. Just overexpression of both the WT and AA construct showed significant 
reduction in mitochondrial length (Additional figure 2B). Interestingly, mitochondrial density 
was also significantly reduced in both MFF WT and AA overexpressed neurons suggesting 
mitochondrial fission may be coupled to degradation (Additional figure 2C). Lastly, a 
correlative reduction of spine density was also observed upon MFF WT and AA overexpression 




















Additional figure 2. Overexpression of MFF WT and AA can alter mitochondrial 
morphology and spine density. (A) Representative images of primary cortical neurons at 21 
DIV electroporated with pCAG-mito-DsRed, pCAG-Venus, and either control, MFF WT or 
MFF AA constructs at E15.5. (B) Quantification of dendritic mitochondrial length (C) 
dendritic mitochondria density (D) spine density for Figure 2.3A. Data is represented by box 
plots displaying minimum to maximum values, with the box denoting 25th, 50th (median) and 
75th percentile from one experiment. Ncontrol  =  25 dendrites,  180 mitochondria; NMFF WT=  18 
dendrites, 199 mitochondria; NMFF AA = 25 dendrites,  290 mitochondria. Statistical analysis 
was performed using Kruskal-Wallis test followed by Dunn’s post-hoc test in (B-C). The test 
was considered significant when p<0.05 with the following criteria: * p<0.05; ** p<0.01; 
***p<0.001; ****p<0.0001; ns, not significant.  
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2.4 Further Discussion 
 Collectively, these results and the additional preliminary data examine the cellular and 
molecular mechanisms underlying Aβ42o-mediated synaptic loss and in particular addressed 
whether or not over-activation of CAMKK2-AMPK causally links mitochondrial remodeling and 
synaptic loss during the early stages of AD. We identified a novel stress response pathway 
linking various cellular defects including mitochondrial remodeling, altered autophagy, and 
synaptotoxicity by Aβ42o. Mechanistically, we show that hyperactivation of the CAMKK2-
AMPK pathway leads to dendritic mitochondrial remodeling through a combination of MFF-
dependent mitochondrial fission and Ulk2-dependent mitophagy. Interestingly, the mitochondrial 
remodeling has a causal effect on  the synaptotoxic effects of Aβ42o. Lastly, we find that in vivo, 
hippocampal CA1 PNs have a unique and highly compartmentalized mitochondrial morphology 
in the apical tuft, where, interestingly, we observed the earliest and most dramatic mitochondrial 
remodeling and dendritic spine loss in J20 AD mice. This summary is represented by schema in 
Additional figure 3.  
 
2.4.1. Disruption on mitochondrial function  
As our results demonstrate, mitochondrial remodeling plays a causal role in Aβ42o-dependent 
synaptic loss. However, exactly how mitochondrial function is disrupted and what function(s) of 
mitochondria triggers synaptic loss is still unclear. Mitochondria play many critical metabolic 
and physiological functions, especially in neurons, including ATP production, phospholipid  
biosynthesis, amino acid production, as well as Ca2+ buffering; interestingly, mitochondrial 




 Therefore, the dramatic Aβ42o-induced MFF- and ULK2-dependent mitochondrial 
fission and loss of biomass strongly suggests that their function is also disrupted. One possible 
consequence of mitochondrial remodeling is reduced Ca2+ buffering capacity, which is of critical 
importance particularly in PNs. In hippocampal PNs, the kinetics of Ca2+ sources governs the 
Additional figure 3. Schema of our model. (A) Schematized CA1 PNs illustrating the 
compartmentalized mitochondrial morphology observed in dendrites of control neurons: fused 
and elongated mitochondrial in apical tufts (slm) and low density of short mitochodnria in 
basal (so) and apical oblique dednrites (sr). Another key aspect of hippocampal circuit 
organization is the high level of laminar specificity of the inputs made onto the dendrites of 
CA1 PNs: for example, the two main types of inputs received by CA1 PNs are inputs from the 
entorhinal cortex (contacting the apical tufts of CA1 PNs in slm) and from CA3 PNs 
(contacting the apical oblique dendrites of CA1 PNs in sr) which are strictly segregated 
spatially. (B-C) We hypothesize, based on our preliminary results that over-activation of the 
CAMKK2-AMPK-MFF-ULK2 pathway leads to mitochondrial fragmentation and decreased 
mitochondrial volume will decrease the ability of mitochondria to buffer cytoplasmic Ca2+ in 
dendrites resulting in accumulation of cytoplasmic Ca2+ postsynaptically, which could lead to 
synaptic loss at early stages of AD progression (C).  
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time course of [Ca2+] signals and may explain the selective activation of long- term synaptic 
potentiation (LTP) and long-term depression (LTD) by NMDA-R-mediated synaptic Ca2+ 
(Sabatini, Oertner, & Svoboda, 2002).Therefore, we predict that the reduction in mitochondrial 
biomass in apical tufts of CA1 PNs described in our results might reduce their Ca2+ buffering 
capacity i.e. increase local cytoplasmic Ca2+ accumulation in this segments of dendrites receiving 
synaptic inputs from the medial entorhinal cortex and impair LTP or even induce LTD instead.  
Recent study from our lab illustrated that dendritic mitochondria are indeed critical for 
buffering Ca2+ in large part due to their interaction with the ER (Hirabayashi et al., 2017). The 
significant reduction of mitochondrial volume upon Aβ42o may reduce available contact site 
with ER that limits intracellular Ca2+ buffering capacity. Another consequence of mitochondrial 
volume reduction is the decrease in sheer surface area of IMM where MCU can import cytosolic 
Ca2+. Interestingly, mitochondria Ca2+ overload has been observed in PNs in vitro upon exposure 
of Aβ42o, which is thought to ultimately lead to the opening of mitochondrial permeability 
transition pore (mPTP), releasing cytochrome c and eventually triggering apoptosis (Sanz-
Blasco, Valero, Rodriguez-Crespo, Villalobos, & Nunez, 2008). Because PNs experience 
changing dynamics of Ca2+ levels, which trigger various intracellular Ca2+ dependent signaling 
pathways, tight regulation of Ca2+ is essential for their maintenance and plasticity (Simms & 
Zamponi, 2014). Disruption of mitochondrial buffering capacity could potentially contribute to 
the Ca2+ buildup that has been associated with AD, and ultimately leads to the excitotoxic effects 
of Aβ42o with further activation of the CAMKK-AMPK pathway.  
 
Another critical function of mitochondria is the production of ATP. Because of the 
polarized structure of PNs, local production of ATP has been long thought to facilitate the 
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complex functions of synaptic activity as well as neuronal survival (Rowland et al., 2000; 
Shepherd & Harris, 1998). Interestingly, levels of various subunits in the ETC, COX subunits II 
and IV, is reduced in AD patient samples as well as various AD mouse models, suggesting 
efficient ATP production is disrupted (Ojaimi, Masters, Opeskin, McKelvie, & Byrne, 1999). 
This is in line with the significant hypometabolic changes observed in patients using 18F-
fluorodeoxyglucose PET scans (Rabinovici et al., 2010). As discussed in the introduction, levels 
of mitochondrial fission and fusion proteins are also altered in various AD models, and recent 
studies have highlighted that mitochondrial dynamics can influence its OXPHOS function (D. C. 
Chan, 2006). Because the fission and fusion machinery can directly influence the surface area of 
IMM as well as proper cristae formation, disruption in the balance of mitochondrial fission and 
fusion can directly influence ATP production.  
 
Alteration in the OXPHOS subunit levels not only influences the sheer concentration of 
ATP production, but also the efficiency of ATP production. One of the natural byproducts of 
ETC is ROS due to the incomplete reduction of oxygen. Cellular ROS levels are tightly regulated 
to prevent ROS induced damage using the antioxidant system. In mitochondria, the superoxide 
radicals produced during OXPHOS is converted to hydrogen peroxide by super oxide dismutase. 
The hydrogen peroxide is then further reduced to water by catalase, glutathione peroxidase, and 
peroxiredoxins (Diebold & Chandel, 2016). In AD, counteracting ROS buildup by either 
overexpression of SOD2 or introduction of mitochondria-targeted antioxidants has been shown 
to protect Aβ42o induced toxicity (Manczak et al., 2010; Massaad, Washington, et al., 2009). In 
support of these previous studies, my preliminary results suggest that high levels of antioxidant, 
NAC, can prevent the Aβ42o induced mitochondrial remodeling and synaptotoxicity 
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(Additional Figure 1). This could be explained by an overproduction of ROS due to inefficient 
OXPHOS, disrupted antioxidant pathway, or a combination of these two events. However, future 
study is necessary to clearly identify what steps of ROS regulation is disrupted. An interesting 
recent study highlights the role of ROS in activating AMPK (Rabinovitch et al., 2017). It is 
difficult to conclude the exact source of AMPK activation upon Aβ42o exposure; whether 
NMDAR dependent Ca2+ or direct mitochondrial stress by Aβ42o first triggers the CAMKK2-
AMPK pathway is unclear. An interesting concept supported by recent study is that mitochondria 
can act as an organelle biosensor in PNs. During LTP, mitochondria undergo a phenomenon 
called “mitoflash,” a transient mitochondrial event where mitochondrial depolarization, ROS 
production, and alkalization of matrix is briefly observed. LTP at a single spine leads to a very 
spatially restricted mitochondrial-flashing phenomenon on nearby dendritic mitochondria. This 
mitoflash is blocked by AP5 and CAMKII inhibitors, suggesting that NMDAR dependent Ca2+ 
influx drives this flashing. Interestingly, lasting structural changes in spines correlated with local 
dendritic mitoflash. The authors hypothesize that mitoflash is necessary for mitochondria to 
trigger specific signaling pathway in a spatially restricted manner to potentially allow 
synchronous synaptic plasticity upon stress or change in environment (Fu et al., 2017). Whether 
this phenomenon occurs in various types of PNs in vivo is unclear, and if so, whether it is 
disrupted in AD remains left to be studied. Nevertheless, the idea that mitochondria can act as a 
stress sensor could serve as one mechanism to activate stress response signaling.  
 
2.4.2. Changes in mitochondrial dynamics.  
Another interesting aspect of mitochondrial homeostasis is mitochondrial motility and 
dynamics. Many of the previously published work examining mitochondrial dynamics has been 
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focused on axons. Work from the Mucke lab has shown that axonal mitochondria decrease their 
trafficking rate in a tau dependent manner in young neuronal cultures (Roberson et al., 2007). 
However, recent work from our laboratory has shown a developmental change in axonal 
mitochondrial trafficking rate, such that at maturity, majority of the axonal mitochondria are 
stationary (Courchet et al., 2013). Therefore, we are starting to recognize the importance of 
studying these models at the right age or at the right maturity stage, and much of the work done 
on axonal mitochondrial dynamics need to be repeated in mature PN cultures. 
Mitochondrial dynamics in dendrites has been less study. Recent studies show that 
dendrites in retinal ganglion cells also undergo age dependent change in mitochondrial 
dynamics, such that mitochondrial dynamic is low at mature stages (Faits, Zhang, Soto, & 
Kerschensteiner, 2016). Interesting future studies can examine if Aβ42o can induce changes in 
dendritic mitochondrial motility in mature PNs.  
 
2.4.3. Role of tau in mitochondrial dynamics 
One concept that the manuscript does not cover is how/whether tau is involved in the 
Aβ42o mitochondrial structural remodeling. Our lab previously published that one of the 
downstream effectors of CAMKK2-AMPK activation is tau. This was a novel finding as it 
demonstrated that the CAMKK2-AMPK signaling pathway is one of the few signaling pathways 
linking Aβ42o with tau phosphorylation, two critical drivers of AD (Mairet-Coello et al., 2013). 
Our new finding shows that MFF and Ulk2 are also downstream effectors of AMPK. So how 
does tau fit into the mitochondrial structural remodeling? This is especially interesting with the 
recent publication linking tau, mitochondrial fission, and synaptic maintenance (DuBoff, Gotz, & 
Feany, 2012). One interesting hypothesis postulates that tau is involved in the altered 
	 113 
mitochondrial dynamics, in part by its role in microtubule-dependent trafficking (Qu et al., 
2017). One fascinating possibility is if AMPK can temporally regulate tau to trigger increased 
mitochondrial dynamics, then later activate MFF and Ulk2 to trigger fission and mitophagy, 
respectively. The role of tau on mitochondria can be tested using Tau KO cultures or by over-
expression of Tau-S262A mutant, a form of tau that cannot be phosphorylated by AMPK which 
is sufficient to protect cortical PNs from Aβ42o-induced synaptic loss; (Mairet-Coello et al., 
2013). These experiments would test if Aβ42o-induced mitochondrial remodeling is also tau-
dependent and therefore if AMPK-dependent phosphorylation of tau could cooperate with MFF- 
and ULK2-dependent mitochondrial remodeling.   
 
 
2.4.4. Link between mitochondria and synaptic maintenance 
 Despite the large volume that dendritic mitochondria occupy, the relationship between 
mitochondria and dendritic/spine maintenance is not extensively studied. Dendritic mitochondria 
are largely excluded from dendritic spines and reside mostly in the dendritic shaft (Kasthuri et 
al., 2015; Y. Wu et al., 2017). Throughout neuronal maturation in vitro, the number of 
mitochondria that does reside in spine decreases (Sheng et al., 2012). One of our preliminary 
result suggests that overexpression of MFF WT or MFF AA is sufficient to reduce mitochondrial 
length and density as well as reduced spine density in vitro (Additional Figure 2). There are 
several interesting observations here. One is the WT and AA form of MFF can both have an 
overexpression effect, suggesting that the AMPK phosphorylation of MFF is not necessary for 
MFF function, but only becomes relevant during stressful conditions. This further confirms our 
view of the CAMKK2-AMPK signaling pathway as a stress response pathway (Mairet-Coello et 
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al., 2013; Mairet-Coello & Polleux, 2014). Another interesting observation is that overexpression 
of MFF and therefore increasing fission also results in reduction of mitochondrial volume, 
suggesting that mitochondrial fission is coupled to degradation/mitophagy. The exact mechanism 
that couples these two events, however, is unclear. And lastly, ultimate reduction of 
mitochondrial volume is sufficient to lead to reduction of spine density, further confirming the 
causal role that mitochondria can have on synapse maintenance.  
 
 2.4.5. Local autophagy in dendrites of PNs 
 The unique polarization of PNs not only influences mitochondrial homeostasis, but also 
other cell biological processes such as autophagy. Much of what we understand behind the 
molecular and cell biology of autophagy is from studies using cell lines (Mizushima, 2007). We 
have only now recently started to understand the unique dynamics of autophagy in PNs, mostly 
focusing on axons. Studies primarily from the Holzbaur lab shed light on how axonal autophagy 
is unique. In basal conditions, the formation of AP by the initiation complex has been primarily 
observed in the distal ends of axons. Interestingly, AP are retrogradely trafficked towards the 
soma where lyososomes are localized to fuse and form AL. Therefore, AP formation and its 
fusion with lysosome occurs at distinct sites along the axon (Maday & Holzbaur, 2016). The 
authors of the paper briefly mention that there is little change in the autophagy dynamics in 
dendrites. Interestingly, our results also suggest that in basal conditions, there are little signs of 
dendritic autophagosome dynamic. However, upon treatment of Aβ42o, we observe dramatic 
accumulation of both AP and lysosomes, suggesting that in the dendrites, autophagy can be 
triggered by stress. Moreover, in our Aβ42o-treated PNs, AP and lysosome fusion is a fast 
process that occurs locally along the distal dendrites, a different dynamic compared to the axons.  
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 Although we observe local accumulation of AP and lysosomes at sites where 
mitochondrial volume is reduced upon Aβ42o exposure, we cannot conclude that these 
lysosomes are fully functional. Studies from the Nixon group have highlighted that in some 
models of AD, primarily with PS1 mutations or deletion, lysosomal acidification and cathepsin 
activation were impaired, in part by disruption of the v-ATPase subunit (J. H. Lee et al., 2010). 
One caveat of these results is that they are largely obtained or observed at relatively late stages of 
the disease progression in AD patients or in mouse models, when neuronal health is 
compromised and neurons start dying by apoptosis. At that stage, observing accumulation of 
autophagosomes/autolysosomes might reflect true neurodegeneration rather than synaptotoxicity. 
 
However, one possible scenario in Aβ42o treated conditions is that mitochondria are in 
fact being targeted properly to AP, and AP can fuse with lysosomes, but the lysosomal contents 
may not be efficiently degraded. There are rare cases in Aβ42o treated PNs where the AL form 
abnormally large puncta over time (data not shown), potentially because AL is not able to 
degrade its cargoes. To test this hypothesis, there are two experiments we could try. One is to try 
staining for endogenous levels of cathepsin to examine if the accumulated lysosomes contain 
proper hydrolases to degrade its contents. A second experiment is to tag a pH sensitive 
fluorophore, such as pHluorin, targeted to the inner side of the lysosome and examine the change 
of lysosomal pH upon Aβ42o treatment. If there is a dysfunction of lysosomal acidification, then 
we would expect to see accumulation of lysosomes without co staining with cathepsin and 
change in the pH levels.  
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2.4.6. Unique mitochondrial morphology of hippocampal PNs 
One of the surprising findings of our paper is that hippocampal PNs have dendritic 
specific mitochondrial morphology and that the distal dendrites, where long mitochondria are 
found, undergo the most significant mitochondrial remodeling and synaptotoxicity. There are 
some interesting open questions to this observation. First is what makes the distal dendrites 
unique? In wildtype mice, these distal dendrites have been shown to possess nonlinear dendritic 
spiking mechanism that provides a strong mechanism for multiplicative input interaction. The 
distal dendrites receive inputs from layer III entorhinal cortex and also display non-linear 
dendritic spiking activity, or also known as dendritic plateau/ dendritic spikes, which results in 
massive influx of Ca2+ (Stuart & Spruston, 2015) One interesting hypothesis is that the long 
mitochondria in distal dendrites are necessary for buffering these large amounts of intracellular 
Ca2+ triggered by activation of VGCC and/or NMDA receptors. 
 
In the context of AD, another interesting question is why the distal dendrites are spatially 
disrupted most dramatically compared to the other dendrites. There are several possibilities for 
this observation. It’s possible that the diffused species of Aβ42o may preferentially localize near 
these distal dendrites, spatially restricting the synaptotoxic effects on PNs. On the other hand, 
these distal dendrites may be especially prone to stressful conditions, especially those that 
interfere with mitochondrial morphology and function. Interestingly, study from the Kittler 
group has shown that conditional KO of Miro1 leads to loss of mitochondrial mass spatially and 
strictly in the distal dendrites in vivo. Dendritic degeneration is observed in distal dendrites and 
eventually neurons display full on ND phenotypes with significant reduction in dendritic 
arborization and length (Lopez-Domenech et al., 2016). In this study, the authors argue that 
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disruption of mitochondrial trafficking in hippocampal PNs reduce mitochondrial mass first in 
the distal dendrites and eventually leads to ND. Similar to our observation, the distal dendrites 
seem to be most vulnerable to these types of “mitochondrial stress.” However, it is difficult to 
conclude whether Aβ42o distinctly localizes closer to distal dendrites, or if distal dendrites are 
intrinsically most vulnerable to stress, or a combination of both.  
 
2.4.7. Endogenous function of Aβ42o 
 One of the lingering questions in the field of AD is what is the endogenous function of 
the Aβ peptides that are generated even in healthy humans? Aβ peptide sequences are 
evolutionarily conserved, but are often thought as just a functionless catabolic byproduct (Luna, 
Cameron, & Ethell, 2013). Interestingly, a family of peptides called anti-microbial peptide 
(AMP) members displays similar characteristics to Aβ as AMPs have a tendency to oligomerize 
and form fibrils as well (Soscia et al., 2010). These AMPs are expressed in brains and other 
regions where adaptive immune systems are restricted and function as first line of defense with a 
large spectrum of antibiotic and immunomodulators to target various microbes. Despite the 
protective role of AMPs, dysfunction of these peptides can lead to cell toxicities including 
chronic inflammation and degenerative pathologies. Interestingly, recent studies highlights that 
Aβ peptide may also have similar anti-microbial function. Whole brain homogenates from AD 
patients show Aβ- mediated activity against pathogenic yeast, Candida albicans. Synthetic Aβ 
peptides can also protect cultured cells from influenza A and herpes simplex virus (White et al., 
2014). Moreover, when comparing wildtype and 5X FAD at 1 month, injection of Salmonella 
typhimurium into the intra-cerebral led to increased survival rate, decreased weight loss, and 
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decreased bacterial load in the 5X FAD mice, suggesting that the abundance of Aβ production 
can actually have beneficial effects upon infection (Kumar et al., 2016). 
 
 The idea of Aβ peptide to function as an anti-microbial is interesting in the context of 
AD. One interesting idea is that there is an age-dependent regulation of anti-microbial function 
where a developing brain may have greater need for anti-microbial properties of Aβ. Perhaps this 
may be down regulated in the adult brain, but age-related insults and or infections could re-
activate these properties of Aβ. One hypothesis is that Aβ can have toxic effects especially on 
mitochondria, potentially because mitochondria could express unique “antigens,” as it was 
originally a bacterium before symbiosis with a ancestral prokaryotic cell occurred. An intriguing 
possibility is that AD pathogenesis is a consequence of exploiting the anti-microbial properties 
of Aβ to target mitochondria that causes various downstream cell toxicities. However, better 
understanding of the mechanisms behind anti-microbial function of Aβ, such as the antigens it 
recognizes, is necessary to understand the role of Aβ peptides in development and ND. 
 
2.4.8. Role of non-neuronal cells in AD 
 This thesis focuses on the cell and molecular biology in PNs during the progression of the 
disease. However, it is important to remember that the CNS is composed of numerous types of 
cells, including microglia, which are recognized to play an essential role in neurodevelopment as 
well as ND. Microglia has gained tremendous interest in the field of AD especially after 
hypomorphic variants of Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), R47H 
and R62H, has been associated with increased risk of sporadic AD (Ulrich, Ulland, Colonna, & 
Holtzman, 2017). TREM2 is a surface receptor expressed primarily on microglia required for 
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their phagocytosis function. Throughout healthy adulthood, the inflammatory response is 
inhibited through receptor-ligand pairs, soluble molecules throughout the CNS milieu, such as 
TGFβ, and intracellular regulators, such as transcription factor MafB. Interestingly, this 
inflammatory response by microglia is activated during neurodevelopment for synaptic pruning 
and also in AD, contributing to synaptotoxicity (Hong, Beja-Glasser, et al., 2016; Keren-Shaul et 
al., 2017). Furthermore, when examining TREM2 KO; 5X FAD mice, they contained increased 
AMPK activation and autophagy with lower mitochondrial mass similar to the observation we 
made in PNs (Ulland et al., 2017). It is currently unclear whether the hyperactivation of AMPK 
is a common response in other cell types in CNS. 
 
A major finding of my work is that mitochondrial dysfunction in PNs has a causal role in 
synaptic loss. Our results demonstrate that pyramidal neurons (PNs) trigger a cell-autonomous 
stress response required for Aβ42o-induced synaptic loss during the early stages of Alzheimer’s 
disease (AD). It would be highly interesting to expand this project to consider how neurons 
interact with other cell types within the context of AD and specifically if the mitochondrial 
remodeling I described in this thesis could be the source of signals triggering microglial-
dependent synaptic elimination. Previous studies have shown that synaptic loss can result from 
the activation of microglia and the subsequent engulfment of spines (Hong, Dissing-Olesen, & 
Stevens, 2016). Moreover, a recent study has shown that microglia undergo changes in AD such 
that disease associated microglia (DAM) develop as a function of disease progression (Keren-
Shaul et al., 2017). Upon DAM activation, microglia initiate the classical complement cascade, 
elevating C1q levels, to engulf synapses (Hong, Dissing-Olesen, et al., 2016). However, the 
signaling mechanism that initiates DAM activation is unclear. Moreover, the C1q receptor itself 
	 120 
that mark spines to be targets of microglial engulfment remain unidentified. Interestingly, one 
mechanism through which neurons interact with other cell types is by exchanging their 
mitochondria and its content (Hayakawa et al., 2016).  
 
While the exact mechanism of mitochondrial exchange between neurons and other cell 
types remains unclear, it has been shown in non-neuronal cells that mitochondria can undergo 
budding to form mitochondria-derived vesicles (MDVs). These MDVs can be exocytosed to 
secrete their contents or present molecules on the plasma membrane, such as antigens (Matheoud 
et al., 2016). Therefore, an interesting future study could examine if PNs form MDVs that upon 
exocytosis (1) secrete signaling molecules to activate microglia leading to the development of 
DAMs and (2) present C1q receptors on the surface of spines leading to their engulfment and 
removal by microglia. This could be an exciting next step to examine how neurons communicate 




























Emerging roles of mitochondria in synaptic transmission and neurodegeneration 
3.1 Introduction 
 Our lab was invited to write a review in the new journal called Current Opinion in 
Physiology that started this year in january 2018. A special issue of the journal focused on the 
function of mitochondria in various cell types and pathophysiological contexts. Our particular 
review is on the roles of mitochondria in neurons, specifically during synaptic transmission and 
neurodegeneration. This article was written by three postdocs, Yusuke Hirabayashi, Seok-Kyu 
Kown, and Tommy Lewis Jr., and myself. I was responsible for writing the “Disruption of 
mitochondrial dynamics and neurodegeneration” section, highlighting recent articles on this 
topic, constructing Table 1, and editing various drafts of the paper.  
 
 Despite the relatively selective death on neuronal subtypes and phenotypic diversity of 
ND, many of the common adult-onset ND has been associated with defects in mitochondrial 
function and or morphology (Schon & Przedborski, 2011). Due to the limitation of space, the 
review only covers the following NDs: AD, Parkinson’s’ Disease (PD), amyotrophic lateral 
sclerosis (ALS), and Huntington’s disease (HD). We cover the changes in mitochondrial quality 
control through fission, fusion, and mitophagy as well as in mitochondrial trafficking in neurons 
in these diseases. And briefly, we cover how non-neuronal cells may also undergo mitochondrial 





































































MFF-dependent mitochondrial fission regulates presynaptic release and axon 











Chapter 4. MFF-dependent mitochondrial fission regulates presynaptic release and axon 
branching by limiting axonal mitochondria size 
 
4.1. Introduction 
 One of the main interests in the Polleux lab is studying how PNs maintain their unique, 
polarized morphology. Polarization of PNs has been extensively characterized and likely 
depends on a combination of extrinsic cues, intracellular signaling pathways, and subcellular 
organelle organization (T. L. Lewis, Jr. et al., 2013). Interestingly, one of the most abundant 
organelle in neurons, mitochondria, has been observed to have very compartmentalized 
morphology where dendritic mitochondria are long and tubular and axonal mitochondria are 
short and punctate (Chicurel & Harris, 1992; Li et al., 2004; Shepherd & Harris, 1998). We were 
particularly interested to understand how PNs regulate mitochondrial size spatially different from 
dendrites and axons, and moreover, what the functional consequence is for this 
compartmentalization. The working hypothesis was that mitochondrial fission exceeds fusion in 
axons and vice versa in dendrites. This study, for the first time, identifies that MFF plays a 
specific role in axons to maintain mitochondrial morphology and function. 
This project was spearheaded by two post-doctorates in the laboratory, Dr. Tommy Lewis 
and Dr. Seok Kyu Kwon. It is completed and posted on BioRxiv, and is also under revision in 
Nature Communication. The experiment I fully contributed is 5e and f, measuring the difference 





















































































































4.3 Further Discussion 
 
 The study examines the role of MFF in regulating mitochondrial size in axons. Upon 
knockdown of MFF, axonal mitochondria increase in length compared to wildtype. Functionally, 
MFF knockdown leads to increased mitochondrial Ca2+ uptake, decreasing cytoplasmic Ca2+ 
levels in the presynaptic sites. This ultimately results in decreased evoked NT vesicle release, 
highlighting the critical role of maintaining proper compartmentalized mitochondrial size. 
Overall, the paper highlights a novel mechanism behind maintaining compartment specific 
mitochondria size, and more importantly, the functional importance of this compartmentalization. 
There are several ideas under the discussion section of the paper that I would like to expand on. 
 
 We discuss about a potential mechanism of the compartmentalized mitochondria size 
between dendrites and axons. One of the potential mechanisms mentioned is that mitochondria 
may be tagged within the soma depending on their size in order for proper trafficking to either 
the dendrite or the axon. One way to test this idea is to isolate dendritic and axonal mitochondria 
and characterize unique proteins on the OMM and test their affinity to different motor adaptors. 
One interesting idea is that these mitochondria could be also tagged not solely by their size but 
also their functional potential. As the paper suggest, axonal mitochondria are not critical for ATP 
production. Mitochondria that have less efficient ATP production may selectively undergo 
fission in the soma and get targeted to the axon where Ca2+ buffering is of greater need.  
 
 Another point of discussion in the paper is why MFF knockdown selectively affects the 
length of axonal mitochondria. One possibility is that MFF dependent fission may actually 
involve other currently unknown accessory proteins. To test this idea, dendritic and axonal 
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mitochondria can be isolated. Then, we can pull-down for MFF for mass spectrometry analysis 
to examine if dendritic MFF and axonal MFF interact with different proteins. Once these 
proteins are identified, we can test if the attachments of different accessory proteins influence the 
affinity of Drp1. Second possibility is that different isoforms of MFF can exist in dendrite versus 
axons with various affinities for Drp1. It is also possible that the different isoforms can have 
affinity for the previously discussed accessory proteins. Lastly, there can be different 
posttranslational modifications on axonal versus dendritic MFF. Previously published paper from 
the Shaw lab highlight that AMPK can phosphorylate MFF under metabolically stressful 
condition to enhance the recruitment of Drp1 (Toyama et al., 2016). It is also likely that MFF 
undergoes various other PTMs.  
 An interesting observation made in the paper is that changing mitochondrial sizes in the 
axon only influences its function to buffer Ca2+ with no detectable change in ATP production, 
membrane potential and redox processes. An interesting question is does changing mitochondrial 
size in dendrites also affect a specific function of mitochondria? This may be tricky to test, as we 
need a way to affect just dendritic mitochondrial length without decreasing the overall density of 
the mitochondria. It would be interesting to test if ATP production, membrane potential, and 
redox process changes upon Aβ42 treatment in Ulk2 KO neurons where only mitochondrial 
fission occur without degradation. In this condition, we are selectively decreasing the length of 
dendritic mitochondria without affecting the total volume of mitochondria. A broader question is, 
does mitochondria have very distinct function in dendrite versus axon? We could potentially 
measure the different functions of mitochondria in dendrites versus axons, but the results will be 







































Chapter 5. Key findings and concluding remarks 
5.1. Key finding #1: Aβ42o leads to hyperactivation of AMPK dependent mitochondrial 
remodeling 
Significance: Studies from the AD field highlights that mitochondrial dysfunction could be a 
central cellular phenotype of AD (Ma et al., 2011; Wang et al., 2008; Zhang et al., 2016). 
However, the molecular mechanisms behind this remodeling remained completely unknown. In 
this dissertation, I identified that hyperactivation of CAMKK2-AMPK pathway by Aβ42o 
induces both mitochondrial fission and mitophagy. Mitochondrial fission and degradation has 
been recognized as a coupled event (D. C. Chan, 2006), and interestingly AMPK regulates both 
MFF-dependent mitochondrial fission and Ulk2-dependent mitophagy (Herzig & Shaw, 2018). 
Surprisingly, mitochondrial fission and degradation are two independent events as Aβ42o 
exposed MFF knockdown PNs did not change their mitochondrial density and Aβ42o exposed 
Ulk2 KO PNs still displayed mitochondrial fission. Most intriguingly, upon Aβ42o exposure, 
phosphomutants of MFF and Ulk2 that cannot be phosphorylated by AMPK are insufficient to 
carry out fission and degradation, respectively, highlighting that AMPK acts as a “master 
regulator” to ensure these events are coordinated. 
  
Future Directions: One gap in our current knowledge is exactly what function of dendritic 
mitochondria is altered due to Aβ42o. In the axons, disrupting mitochondrial fusion/fission 
balance such that we make the mitochondria longer can increase their Ca2+ buffering capacity. 
This ultimately reduces the presynaptic cytoplasmic Ca2+, resulting in reduction of evoked NT 
vesicle release. Interestingly, axonal mitochondrial size did not influence any detectable change 
in ATP production and redox processing, highlighting that mitochondria can have a very specific 
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function (Chapter 4). We know the basic morphology of mitochondria is vastly different in 
dendrites compared to axons. How Aβ42o induced mitochondrial fragmentation and degradation 
affects their function still needs to be tested. One attractive hypothesis is that the total Ca2+ 
buffering capacity of dendritic mitochondria is reduced upon Aβ42o treatment, purely due to the 
reduction in their total volume. An interesting experiment is to observe both mitochondrial and 
cytoplasmic Ca2+ dynamics in WT and Ulk2 KO PNs upon Aβ42o exposure. I would 
hypothesize that upon Aβ42o treatment, WT neurons will show increased cytoplasmic Ca2+ due 
to reduced mitochondrial volume where as Ulk2 KO neurons will show no significant change 
due to the maintained mitochondrial volume. If this is true, we can also conclude that reduction 
of mitochondrial Ca2+ buffering capacity is in part causal to Aβ42o induced synaptotoxicity.  
  
 Another interesting point to discuss is evaluating the temporal dynamics of these 
molecular/cellular events: Does the CAMKK2-AMPK hyperactivation occur first, leading to 
changes in mitochondrial density and ultimately their overall function purely due to the reduction 
in volume of mitochondria? Or can Aβ42o influence mitochondrial function directly that results 
in activating CAMKK2-AMPK pathway? To test this idea, we would first need to characterize 
what function of mitochondria is altered. Then we can examine if mitochondrial function is 
disrupted upon Aβ42o in MFF knockdown PNs where mitochondrial length is still long. If 
Aβ42o treatment on MFF knockdown PNs does not alter mitochondrial function, the signaling 
pathway is activated first to remodel mitochondria. If Aβ42o treated MFF knockdown PNs do 
change in function, this means Aβ42o can independently influence mitochondrial function 
without remodeling. If the later scenario is true, resolving the temporal resolution will be 
challenging as we would need to observe AMPK activation and mitochondrial function in live 
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PNs upon acute treatment of Aβ42o. My hypothesis is that there is a bidirectional signaling, 
where Ca2+ influx from extracellular space (Shankar et al., 2007) can activate CAMKK2-AMPK 
to remodel mitochondria, but the disrupted mitochondrial function, i.e. reduction of Ca2+ 
buffering, can lead to cytoplasmic Ca2+ buildup that can further activate CAMKK2-AMPK as 
part of a vicious cycle.  
 
5.2. Key finding #2: Mitochondrial remodeling has a causal function in Aβ42o induced 
synaptotoxicity 
Significance: As highlighted in Chapter 1, Aβ42o induced mitochondrial remodeling and 
synaptotoxicity are two cellular phenotypes observed in AD. For the first time, we highlight that 
mitochondrial remodeling has a causal role in synapse maintenance in the context of AD. 
Because we were able to identify that Aβ42o induces MFF-dependent mitochondrial fission and 
Ulk2 dependent mitophagy, we were able to use various genetic manipulation to study the effects 
of mitochondrial remodeling on spines. Most interestingly, knockdown of MFF is sufficient to 
block Aβ42o induced mitochondrial fission and this is sufficient to protect PNs from 
synaptotoxicity. Because MFF directly regulates mitochondrial fission, and knockdown of MFF 
in basal condition does not influence spine density, we can conclusively say that mitochondrial 
remodeling has a causal role in spine loss in the context of AD. However, we have to be cautious 
about stating mitochondrial remodeling broadly. When we look at Aβ42o treated Ulk2 KO PNs, 
mitochondrial fission still occurs without significant change in their density, which is sufficient 
to protect PNs from synaptotoxicity. Therefore, it is mitochondrial remodeling that ultimately 
results in the reduction of mitochondrial volume that causes Aβ42o induced synaptotoxicity. 
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Future Directions: Mitochondrial remodeling and synaptotoxicity are two of the many cellular 
phenotypes observed in AD models. How does mitochondrial remodeling influence other cellular 
phenotypes such as Ca2+ dyshomeostasis and altered autophagy? To test this idea, we can use a 
combination of genetic manipulation and live imaging. First, many reports have highlighted an 
early excitatory effect where cytosolic Ca2+ build up in AD models (Busche et al., 2012; Demuro 
et al., 2005; Guo et al., 1999; Kuchibhotla et al., 2008). It would be intriguing to test if the 
cytoplasmic Ca2+ build up is prevented upon MFF knockdown or Ulk2 KO as discussed 
previously. We also observe acute accumulation of LC3 and LAMP1 upon treatment of Aβ42o. 
How does the dynamic of autophagy change upon MFF knockdown or genetic ablation of Ulk2? 
Do the initial formations of AP still occur without any mitochondria degradation or is the 
initiation of AP formation itself completely prevented? These are some interesting questions that 
could be further investigated. 
 
5.3. Key finding #3: Hippocampal PNs display dendritic specific mitochondrial morphology 
and the distal dendrites undergo the most dramatic mitochondrial remodeling and synaptic 
loss  
Significance: To test if mitochondrial remodeling and synaptotoxicity are observed in vivo, we 
conducted IUE survival surgery in WT and J20 AD mouse model. Initial finding from a post-
doctorate in the Polleux lab, Dr. Tommy Lewis, showed that hippocampal PNs displayed 
compartmentalized dendritic specific mitochondrial morphology: the basal and oblique dendrites 
are characterized by small and punctate mitochondria whereas the distal dendrites display long 
and tubular mitochondria. Surprisingly, in J20 AD mouse models, the distal dendrites showed the 
most dramatic mitochondrial remodeling and synaptotoxicity. The basal and oblique dendrites 
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had either mild or a trend in these two cellular phenotypes. This data further supported our in 
vitro observations.  
 
Future Directions: One interesting question that arises from my observations is what makes the 
distal dendrites more vulnerable. Are these distal dendrites intrinsically more vulnerable 
compared to the basal and oblique ones? Or are they exposed to more external toxicity in AD 
models? As discussed in the manuscript, the distal dendrites are unique as they undergo a 
phenomena called dendritic plateau, where they massively uptake high levels of Ca2+. In the 
context of AD, if PNs undergo an initial excitatoxicity where Ca2+ further enters the cell, the 
distal dendrites may be the first to experience Ca2+ overload where they are already handling 
high level of Ca2+. Another possibility is that these distal dendrites are more vulnerable purely 
because Aβ42o production is higher in these region. It is difficult to stain the different species of 
Aβ42o, but an interesting experiment would be to surgically remove specific parts of the 
hippocampus to measure Aβ42 levels by ELISA. Lastly, one of the challenges in studying many 
of the age-related ND is that there is no one single best model. Each AD mouse model captures 
certain characteristics of sporadic AD, but not all the pathophysiology of the disease. Therefore, 
a supporting experiment is to test this phenotype in various AD models, including those that also 
display NFT. Another interesting model to confirm this phenotype is in the APP knockin mouse 
that does not overexpress APP. Instead, APP with KM670/671NL Swedish mutation and I716F 





5.4 Concluding Remarks  
AD continues to be the most common ND with no effective treatment. Elucidating the 
cell and molecular mechanism of mitochondrial alteration and synaptotoxicity by Aβ42o in PNs 
will be fundamental to understanding the early pathophysiology of AD that could potentially 
open doors for novel therapeutic targets. In this dissertation, we sought to characterize key events 
involved in the early stages of AD. We, for the first time, identify the causal role of 
mitochondrial remodeling in Aβ42o induced synaptic loss. This cellular event is regulated by 
hyperactivation of AMPK that regulates MFF-dependent mitochondria fission and Ulk2-
dependent autophagy. We also observe that in vivo hippocampal PNs have very unique dendritic 
compartmentalized morphology and that the distal apical dendrites display the most vulnerability 
to Aβ42o. Collectively, our results serve as a significant contribution to our understanding of the 
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